4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4h-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide-based pharmaceutical substance for producing antibacterial medicinal preparations and pharmacuetical composition based on said substance

A pharmaceutical substance with 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide, formulated with controlled particle sizes, addresses solubility and bioavailability issues, enhancing antibacterial efficacy and safety.

WO2026235569A1PCT designated stage Publication Date: 2026-11-12FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE UCHREZHDENIE NATSIONALNYJ ISSLEDOVATELSKIJ TSENTR EPIDEMIOLOGII I MIKROBIOLOGII IMENI POCHETNOGO AKADKA N F GAMALEI MINISTSTVA ZDRAVOOKHRANENIYA ROSSIJSKOJ FEDERATSII
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/RU2025/000394
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2025-12-10
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current T3SS inhibitors for Gram-negative bacteria face challenges with poor solubility in organic solvents and water, toxicity to mammalian cells, and low bioavailability, limiting their development as effective antibacterial agents.

Method used

A pharmaceutical substance containing 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide is formulated with particles of specific modal sizes (≤45.9 μm) and used in a composition with pharmaceutically acceptable excipients to enhance bioavailability and safety.

Benefits of technology

The formulation achieves increased bioavailability, allowing for effective antibacterial therapy, including monotherapy and prevention of nosocomial infections, with reduced adverse reactions and improved solubility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000017_0001
    Figure IMGF000017_0001
  • Figure IMGF000035_0001
    Figure IMGF000035_0001
  • Figure IMGF000046_0001
    Figure IMGF000046_0001
Patent Text Reader

Abstract

The present invention relates to the chemical and pharmaceutical industry and to medicine, and specifically to the field of medical microbiology and the development of antibacterial preparations. The technical result of the invention consists in a pharmaceutical substance which contains a type III secretion system inhibitor, 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4Н-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide, and exhibits enhanced bioavailability and a favourable safety profile, and a pharmaceutical composition based on said substance. This technical result is achieved by the creation of a pharmaceutical substance for producing antibacterial medicinal preparations which contains 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4Н-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide, in which the active ingredient is present in the form of particles having a modal size which is less than or equal to 45.9 µm, and may also be in a crystalline or an amorphous form. The technical result is further achieved by the creation of an antibacterial pharmaceutical composition containing the claimed pharmaceutical substance and pharmaceutically acceptable excipients. In a specific embodiment, the pharmaceutically acceptable excipients may be selected from among a filler, a disintegrant, a surface modifier, a binder, and a glidant. Also proposed is the use of the pharmaceutical composition to produce a finished dosage form in the form of a tablet. Further proposed is the use of the pharmaceutical composition to produce a finished dosage form in the form of a powder.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] A pharmaceutical substance for the formation of antibacterial medicinal products based on 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide and a pharmaceutical composition based on it.

[0002] Field of technology

[0003] The present invention relates to the chemical-pharmaceutical industry and medicine, and, in particular, to the field of medical microbiology and the development of antibacterial drugs.

[0004] State of the art

[0005] The emergence and rapid evolution of multidrug-resistant strains is a serious public health concern. In 2019, approximately 13.7 million infection-related deaths were recorded globally. Antimicrobial resistance-related diseases (AMR) directly caused approximately 1.27 million deaths and indirectly caused 4.95 million deaths [S. Ho et al. Antimicrobial resistance: a concise update. The Lancet Microbe, Volume 6, Issue 1, 100947]. The 2022 Global Antimicrobial Resistance and Use Surveillance System (GLASS) report also provides alarming data on the prevalence of resistance among prevalent bacterial pathogens.According to the study results, in 76 countries, the average rate of resistance of E. coli to third-generation cephalosporins was 42%, and of Staphylococcus aureus to methicillin was 35%, which caused serious concern to the World Health Organization (WHO) [https: / / www.who.int / news-room / fact-sheets / detail / antimicrobial-resistance].

[0006] Growing antibiotic resistance among pathogens seriously limits clinicians' ability to combat bacterial infections, leading to longer hospital stays and increased patient mortality. Meanwhile, the development of new drugs is progressing extremely slowly. According to the WHO, 13 new antibiotics were approved globally between 2017 and 2024, but only two of these belong to a new chemical class and can be considered innovative. This highlights the scientific and technical complexity of finding new antibacterial drugs that are effective against bacteria and safe for humans, as well as the need to identify new targets for antimicrobial action.

[0007] The emergence and spread of resistance among microorganisms is a natural process that arose long before the discovery of antibiotics. Bacteria acquire random mutations in genes encoding the target or transport of antibiotics, or encoding enzymes that destroy antibiotics, etc. These mutations render them resistant to antibacterial drugs and provide a competitive advantage in survival. Antibiotic resistance genes can be transmitted through vertical inheritance (from ancestors to descendants) or through horizontal gene transfer (the process by which an organism transfers genetic material to another organism that is not its descendant). Many researchers emphasize the importance of normal human microflora as a reservoir of resistance genes that can be transmitted to pathogens.Thus, there is currently a need to develop effective and safe antibacterial drugs that do not cause selective pressure on pathogenic bacteria and have minimal impact on normal human microflora.

[0008] A promising approach to reducing selective pressure is to select pathogen molecular targets that will not affect the growth and survival of microorganisms but will limit their virulence. One such target is the bacterial type 3 secretion system (T3SS).

[0009] The T3SS, also known as the injectosome or molecular syringe, is a protein complex that facilitates the transport of bacterial proteins into eukaryotic cells. The type III secretion system has been identified in a number of Gram-negative bacteria that cause socially significant and particularly dangerous infections, such as enteropathogenic and enterohemorrhagic Escherichia coli, Salmonella enterica, Chlamydia spp., Yersinia pestis, Vibrio spp., Shigella spp., and Pseudomonas spp. Mutations that disrupt even one T3SS component lead to a decrease or loss of virulence. Moreover, T3SS proteins from even taxonomically distant microbial genera share a high degree of homology, making them a universal target for several pathogens.

[0010] A number of technical solutions related to the production of T3SS inhibitors for Gram-negative bacteria are known in the art. These include low-molecular-weight compounds of various classes, as well as specific antibodies to the T3SS structural protein.

[0011] The most well-studied class of T3SS inhibitors are salicylidene acylhydrazides. Their activity as T3SS inhibitors has been demonstrated in Y. pestis, Chlamydia spp., Salmonella enterica serotype Typhimurium (S. Typhimurium), Shigella spp., EHEC, Xanthomonas oryzae, and Erwinia amylovora [https: / / www.mdpi.com / 2218-273X / 11 / 2 / 316]

[0012] Phenoxyacetamide and its derivatives are also known to inhibit the T3SS of Pseudomonas aeruginosa [Bowlin, NO; Williams, JD; Knoten, CA; Torhan, MC; Tashjian, TF; Li, B.; Aiello, D.; Mecsas, J.; Hauser, AR; Peet, NP; et al. Mutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system. Antimicrob. Agents Chemother. 2014, 58, 2211–2220].

[0013] A technical solution is known in which piericidin A is used as an inhibitor of the Yersinia pseudotuberculosis T3SS [Duncan, M.C.; Wong, WR; Dupzyk, AJ; Bray, WM; Linington, RG; Auerbuch, V. An NF-KB-based high-throughput screen identifies piericidins as inhibitors of the Yersinia pseudotuberculosis type III secretion system. Antimicrob. Agents Chemother. 2014, 58, 1118–1126. Auerbuch, V.; Golenbock, DT; Isberg, RR. Innate immune recognition of Yersinia pseudotuberculosis type III secretion. PLoS Pathog. 2009, 5].

[0014] In another technical solution, α-Hydroxybenzimidazole is used as an inhibitor of Yersinia spp. T3SS [Kim OK, et al. 2009. N-hydroxybenzimidazole inhibitors of the transcription factor LcrF in Yersinia: novel antivirulence agents. J. Med. Chem.

[0015] 52:5626-5634].

[0016] A technical solution is also known in which dipropionic acid and its derivatives are used as an inhibitor of the Yersinia spp. T3SS [Pan N, Lee C, Goguen J. 2007. High throughput screening for small-molecule inhibitors of type III secretion in Yersinia pestis. Adv. Exp. Med. Biol. 603:367-375].

[0017] The prior art discloses Caminoside A, isolated from the marine sponge Caminus sphaeroconia, which demonstrated high activity in screening for T3SS inhibitors [Linington RG, et al. 2002. Caminoside A, an antimicrobial glycolipid isolated from the marine sponge Caminus sphaeroconia. Org. Lett. 4:4089^1092]. A technical solution is known in which Aurodox is used as a T3SS inhibitor [Kimura K, et al. 2011. A small-molecule inhibitor of the bacterial type III secretion system protects against in vivo infection with Citrobacter rodentium. J. Antibiot. (Tokyo) 64:197-203].

[0018] Common disadvantages of these compounds include poor solubility in organic solvents and / or water; toxicity to mammalian cell cultures (death of up to 60% of cells in the presence of a specific inhibitory concentration of 50 μM). These significant drawbacks limit their potential for further development as antibacterial agents.

[0019] The prior art also discloses a pharmaceutical composition comprising the active ingredient 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in crystalline form with a particle size of less than 50 μm in an amount of 150 to 600 mg in the form of an oral solid dosage form with acceptable excipients (patent RU2737087C1). This technical solution, as the closest to the claimed one in terms of the composition of the active substance and the method of its use, was chosen by the authors of the claimed invention as a prototype. The main disadvantage of the prototype is the low bioavailability of the active substance.

[0020] Thus, there is currently a need to develop a pharmaceutical substance based on a bacterial T3SS inhibitor with high bioavailability and a pharmaceutical composition based on it.

[0021] The technical problem solved in the present invention was the development of a pharmaceutical substance for the treatment of infectious diseases based on a T3SS inhibitor, capable of being effectively released from the dosage form and possessing increased bioavailability.

[0022] Disclosure of the essence of the invention

[0023] The technical result achieved in the present invention is the creation of a pharmaceutical substance containing an inhibitor of the type III secretion system 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide, which has increased bioavailability, as well as a favorable safety profile and in the creation of a pharmaceutical composition based on it.

[0024] The specified technical result is achieved by the fact that a pharmaceutical substance has been created for the formation of antibacterial medicinal preparations, containing 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide, wherein the active substance is contained in the form of particles that have a modal size less than or equal to 45.9 μm.

[0025] In this case, 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide can have a crystalline or amorphous form.

[0026] In a particular case, the modal particle size of a pharmaceutical substance is 45.9 µm. In another case, the pharmaceutical substance contains particles with a modal size of 40.8 µm. Furthermore, the modal particle size of a pharmaceutical substance may be 10.0 µm. In yet another case, the pharmaceutical substance contains particles with a modal size of 7.1 µm.

[0027] The technical result is also achieved by creating a pharmaceutical composition with antibacterial action, containing the developed pharmaceutical substance and pharmaceutically acceptable excipients. In this particular case, pharmaceutically acceptable excipients may be selected from a filler, a disintegrating agent, a surface modifier, a binder, or a lubricant.

[0028] The use of a pharmaceutical composition for obtaining a finished dosage form of a tablet has been developed.

[0029] In addition, the use of a pharmaceutical composition for obtaining a finished dosage form of powder has been developed.

[0030] The developed pharmaceutical composition is used for antibacterial therapy. In particular, antibacterial therapy is administered against pathogenic or opportunistic bacteria. Antibacterial therapy is also used against bacteria with extracellular or intracellular parasitism. Furthermore, antibacterial therapy is used against bacteria that cause acute or chronic infections. In another case, antibacterial therapy is used against bacteria that cause recurrent diseases. A use for the pharmaceutical composition has been developed in which it is administered concurrently with an antibiotic.

[0031] An application of the pharmaceutical composition has also been developed in which it is used as monotherapy.

[0032] In another application, the pharmaceutical composition is used to prevent nosocomial infections. In this particular case, the nosocomial infection is nosocomial pneumonia.

[0033] One application of the pharmaceutical composition is to inhibit biofilm growth. Another application is to reduce bacterial motility. Another application is to reduce bacterial virulence.

[0034] A pharmaceutical composition has also been developed for use in mammals at a dose containing between 1 mg and 12,600 mg of the active ingredient. In a specific case, the pharmaceutical composition is administered to mammals at a dose containing 300 mg, 600 mg, or 1,200 mg of the active ingredient.

[0035] Brief description of the figures.

[0036] In Fig. 1

[0037] The scheme of chemical synthesis of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide is presented, where

[0038] I - 2,4-difluoroaniline;

[0039] II - chloroacetyl chloride;

[0040] III - 2-chloro-N-(2,4-difluorophenyl)-acetamide;

[0041] IV - 2-morpholin-4-yl-2-thioxo-N-(2,4-difluorophenyl)-acetamide;

[0042] V - 2-hydrazino-2-thioxo-N-(2,4-difluorophenyl)-acetamide;

[0043] VI - 2-[N'-(3-ethoxy-4-hydroxy-benzylidene)-hydrazino]-2-thioxo-N-(2, 4-difluorophenyl)-acetamide;VII - 2-[N'-(3-ethoxy-4-hydroxy-benzyl)-hydrazino]-2-thioxo-N-(2,4-Difluorophenyl)-acetamide;

[0044] VIII - 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide.

[0045] In Fig. 2

[0046] A diagram of the particle size distribution of the developed pharmaceutical substance, ground for 2 minutes, is presented, where

[0047] on the abscissa axis - particle size, µm

[0048] along the ordinate axis:

[0049] Diff% is the difference percentage between two particle size distributions (difference percentage, Diff%).

[0050] Int% - intensity of light scattering (Intensity Percentage, %).

[0051] In Fig. 3

[0052] A diagram of the particle size distribution of the developed pharmaceutical substance, ground for 4 minutes, is presented, where

[0053] on the abscissa axis - particle size, µm

[0054] along the ordinate axis:

[0055] Diff% is the difference percentage between two particle size distributions (difference percentage, Diff%).

[0056] Int% - intensity of light scattering (Intensity Percentage, %).

[0057] In Fig. 4

[0058] A diagram of the particle size distribution of the developed pharmaceutical substance, ground for 6 minutes, is presented, where

[0059] on the abscissa axis - particle size, µm

[0060] along the ordinate axis:

[0061] Diff% is the difference percentage between two particle size distributions (difference percentage, Diff%).

[0062] Int% - intensity of light scattering (Intensity Percentage, %).

[0063] Fig. 5 shows a diagram of the particle size distribution of the developed pharmaceutical substance, ground for 10 minutes, where

[0064] on the abscissa axis - particle size, µm

[0065] along the ordinate axis:

[0066] Diff % is the difference between two particle size distributions (difference percentage, Diff%).

[0067] Int% - intensity of light scattering (Intensity Percentage, %).

[0068] In Fig. 6

[0069] The average dissolution profile of tablets with different degrees of grinding of the pharmaceutical substance in 4% SLS is presented, where

[0070] the diamond indicates the dissolution profile of the pharmaceutical composition 3

[0071] The square indicates the dissolution profile of the pharmaceutical composition 2 The triangle indicates the dissolution profile of the pharmaceutical composition 1 The cross indicates the dissolution profile of the prototype

[0072] In Fig. 7

[0073] The average dissolution profile of tablets with different degrees of grinding of the pharmaceutical substance in 2% SLS is presented, where

[0074] the diamond indicates the dissolution profile of the pharmaceutical composition 3

[0075] The square indicates the dissolution profile of the pharmaceutical composition 2 The triangle indicates the dissolution profile of the pharmaceutical composition 1 The cross indicates the dissolution profile of the prototype

[0076] In Fig. 8

[0077] The kinetics of changes in the concentration of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in the blood of healthy volunteers after taking the drug at a dose of 1800 mg are presented.

[0078] The abscissa axis is the time after taking the drug, hours.

[0079] The ordinate axis is the concentration of the drug in the blood, ng / ml.

[0080] In Fig. 9

[0081] The kinetics of changes in the concentration of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in the blood of healthy volunteers after taking the drug at a dose of 2400 mg are presented. The abscissa axis is the time after taking the drug, hours.

[0082] The ordinate axis is the concentration of the drug in the blood, ng / ml

[0083] In Fig. 10

[0084] The kinetics of changes in the concentration of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in the blood of healthy volunteers after a course of administration of the drug at a dose of 1800 mg is presented.

[0085] The abscissa axis is the time after taking the drug, hours.

[0086] The ordinate axis is the concentration of the drug in the blood, ng / ml

[0087] In Fig. 11

[0088] The kinetics of changes in the concentration of the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in the blood of healthy volunteers after a course of treatment with the drug at a dose of 1800 mg are presented.

[0089] The abscissa axis is the time after taking the drug, hours.

[0090] The ordinate axis is the concentration of the drug in the blood, ng / ml

[0091] In Fig. 12

[0092] A comparative analysis of the average pharmacokinetic profiles for 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in the whole blood of volunteers after daily and course administration of the drug at a dose of 1800 mg is presented.

[0093] The abscissa axis is the time after taking the drug, hours.

[0094] The ordinate axis is the concentration of the drug in the blood, ng / ml

[0095] A marker in the form of a circle is a course of treatment, a marker in the form of a triangle is a daily treatment.

[0096] In Fig. 13

[0097] A comparative analysis of the average pharmacokinetic profiles for the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in the whole blood of volunteers after daily and course administration of the drug at a dose of 1800 mg is presented.

[0098] The abscissa axis is the time after taking the drug, hours.

[0099] The ordinate axis is the concentration of the drug in the blood, ng / ml

[0100] The marker in the form of a circle is a course reception, the marker in the form of a triangle is a daily reception. In Fig. 14

[0101] The results of evaluating the effect of a pharmaceutical composition on the motility of the Pseudomonas aeruginosa CL-2943 isolate are presented. Bacterial motility was assessed based on the diameter (mm) of the bacterial migration zone from the center of the dish.

[0102] A. Photograph of a control Petri dish with agar medium without the addition of the pharmaceutical composition, 24 hours after the inoculation of bacteria.

[0103] B. Photograph of a Petri dish with an agar medium into which the pharmaceutical composition was added at a concentration of 100 μg / ml, 24 hours after inoculation of bacteria.

[0104] In Fig. 15

[0105] The results of the effect of FC5 on lung colonization in a model of experimental pulmonary infection caused by the B. cenocepacia isolate GIMC4612:Bcn34P14 are presented. The bacterial load in the lungs of mice was determined on days 2, 5, 7, and 10 after infection with B. cenocepacia GIMC4612:Bcn34P14.

[0106] The circle marker shows the bacterial load in control animals infected with B. cenocepacia that were not treated (Всп34Р14).

[0107] The triangle-shaped marker shows the bacterial load in animals infected with B. cenocepacia, which were given prophylaxis and treatment with the developed pharmaceutical composition (Vsp34P14+FT).

[0108] X-axis – time after infection, days.

[0109] The ordinate axis is the titer of bacteria in the lungs of animals, log 10, CFU / ml of tissue

[0110] In Fig. 16

[0111] The graph of survival of animals infected with the clinical isolate of B. cenocepacia GIMC4612:Bcn34P14 at a dose of 10 is presented 8 CFU / mouse.

[0112] The solid line shows the survival rate of animals in the control group after infection with the clinical isolate of B. cenocepacia.

[0113] The dashed line shows the survival rate of animals in the experimental group after infection with a clinical isolate of B. cenocepacia, under conditions of prophylaxis and therapy with the developed pharmaceutical composition.

[0114] X-axis – time after infection, days.

[0115] The ordinate axis is the survival rate of animals, % In Fig. 17

[0116] A graph of the survival rate of animals infected with P aeruginosa GIMC5O36:PA150608 after therapy with the developed composition and / or the antibiotic Meropenem is presented (summarized data from two experiments are provided).

[0117] The solid line with a square marker represents the group of animals infected with P. aeruginosa that received monotherapy with the developed pharmaceutical composition.

[0118] The solid line with a triangle marker represents a group of animals infected with P. aeruginosa that received combination therapy with the developed pharmaceutical composition and Meropenem.

[0119] The solid line with a circle marker represents the group of animals infected with P. aeruginosa that received Meropenem monotherapy.

[0120] The dashed line with a diamond marker represents the control group of animals infected with P. aeruginosa that did not receive treatment.

[0121] X-axis – time after infection, days.

[0122] The ordinate axis is the survival rate of animals, %

[0123] In Fig. 18

[0124] A graph of the survival rate of animals infected with P. aeruginosa GIMC5O36:PA150608 (summarized data from two experiments) after therapy with the developed composition and / or the antibiotic Jamsul is presented.

[0125] The solid line with a square marker represents the group of animals infected with P. aeruginosa that received monotherapy with the developed pharmaceutical composition.

[0126] The solid line with a triangle marker represents a group of animals infected with P. aeruginosa that received combination therapy with the developed pharmaceutical composition and Jamsul.

[0127] The solid line with a circle marker represents the group of animals infected with P. aeruginosa that received monotherapy with Jamsul. The dashed line with a diamond marker represents the control group of animals infected with P. aeruginosa that did not receive therapy.

[0128] X-axis – time after infection, days.

[0129] The ordinate axis is the survival rate of animals, %

[0130] In Fig. 19

[0131] A graph of the survival rate of animals infected with P aeruginosa GIMC5O36:PA150608 (summarized data from two experiments) after therapy with the developed composition and / or the antibiotic Ciprofloxacin is presented.

[0132] The solid line with a square marker represents the group of animals infected with P. aeruginosa that received monotherapy with the developed pharmaceutical composition.

[0133] The solid line with a triangle marker represents a group of animals infected with P. aeruginosa that received combination therapy with the developed pharmaceutical composition and Ciprofloxacin.

[0134] The solid line with a circle marker represents the group of animals infected with P. aeruginosa that received monotherapy with Ciprofloxacin.

[0135] The dashed line with a diamond marker represents the control group of animals infected with P. aeruginosa that did not receive treatment.

[0136] X-axis – time after infection, days.

[0137] The ordinate axis is the survival rate of animals, %

[0138] In Fig. 20

[0139] A graph showing the effect of different doses of the developed pharmaceutical composition on the biofilm-forming ability of S. aureus is presented. The solid line with a square marker shows the biofilm-forming ability of S. aureus 21018.

[0140] The solid line with a triangle marker shows the biofilm-forming ability of S. aureus ATCC 6538. The solid line with a circle marker shows the biofilm-forming ability of S. aureus 25008.

[0141] The abscissa axis is the experimental groups, where:

[0142] K+ - control wells to which the developed composition was not added;

[0143] FT 60 μg / ml - wells into which the developed composition was added at a concentration of 60 μg / ml;

[0144] FT 100 μg / ml - wells into which the developed composition was added at a concentration of 100 μg / ml;

[0145] The ordinate axis is the change in the staining of biofilms with crystal violet in % of K+

[0146] Fig. 21 shows micrographs of biofilms at 240x magnification. х

[0147] a - S. aureus ATCC 6538 control sample,

[0148] b - S. aureus ATCC 6538 with the addition of 60 μg / ml of the developed pharmaceutical composition,

[0149] in - S. aureus ATCC 6538 with the addition of 100 μg / ml of the developed pharmaceutical composition,

[0150] g- S. aureus 21018 control sample,

[0151] d - S. aureus 21018 with the addition of 60 μg / ml of the developed pharmaceutical composition,

[0152] e - S. aureus 21018 with the addition of 100 μg / ml of the developed pharmaceutical composition,

[0153] f- S. aureus 25008 control sample,

[0154] z - S. aureus 25008 with the addition of 60 μg / ml of the developed pharmaceutical composition,

[0155] and - S. aureus 25008 with the addition of 100 μg / ml of the developed pharmaceutical composition,

[0156] Fig. 22: Micrographs reflecting the dynamics of biofilm formation, magnification 240 х a - S. aureus 25008 control sample, 24 hours;

[0157] b - '. aureus 25008 with the addition of 100 μg / ml of the developed pharmaceutical composition, 24 hours;

[0158] c - S. aureus 25008 control sample, 48 hours;

[0159] g - S. aureus 25008 with the addition of 100 μg / ml of the developed pharmaceutical composition, 48 hours

[0160] Fig. 23 Electron micrograph demonstrating the effect of the drug 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide on biofilm formation.

[0161] a - S. aureus 25008 control sample, 24 hours;

[0162] b - S. aureus 25008 with the addition of 100 μg / ml of the developed pharmaceutical composition, 24 hours

[0163] Fig. 24 shows

[0164] A: Electron micrograph showing biofilm formation by E. coli isolate GIMC1402:EC-33P15 after 24 h (1), 48 h (2), and 72 h (3).

[0165] B: Electron micrograph showing the accumulation of exopolysaccharide matrix by biofilm of E. coli isolate GIMC1402:EC-33P15 after 24 h (1), 48 h (2), and 72 h (3). C: Electron micrograph showing the effect of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide on biofilm formation by E. coli GIMC1402:EC-33P15 after 24 h (1), 48 h (2), and 72 h (3).

[0166] D: Electron micrograph showing the effect of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide on exopolysaccharide matrix production by E. coli GIMC1402:EC-33P15 biofilm after 24 h (1), 48 h (2), and 72 h (3).

[0167] E: Graph showing biofilm formation by E. coli isolate GIMC1402:EC-33P15 after 24 h (1), 48 h (2) and 72 h (3).

[0168] The abscissa axis is the growth time of the bacterial culture, hours. The ordinate axis is the growth of biofilms (OP540).

[0169] F: Graph showing the accumulation of exopolysaccharide matrix by the biofilm of E. coli isolate GIMC1402:EC-33P15 after 24 h (1), 48 h (2), and 72 h (3).

[0170] The abscissa axis is the growth time of the bacterial culture, hours.

[0171] The y-axis is biofilm growth (OP492).

[0172] G: Graph showing the effect of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide on biofilm formation of E. coli GIMC1402:EC-33P15 at 24 h (1), 48 h (2) and 72 h (3).

[0173] The abscissa axis is the growth time of the bacterial culture, hours.

[0174] Y-axis - biofilm growth (OP540)

[0175] Gray columns - control, E. coli culture without the addition of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide

[0176] Columns filled with checkerboard pattern - E. coli culture with the addition of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide.

[0177] H: Graph showing the effect of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide on exopolysaccharide matrix production by biofilm of E. coli isolate GIMC1402:EC-33P15 after 24 h (1), 48 h (2) and 72 h (3).

[0178] The abscissa axis is the growth time of the bacterial culture, hours.

[0179] Y-axis - biofilm growth (OP492)

[0180] Gray columns - control, E. coli culture without the addition of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide

[0181] Columns filled with checkerboard pattern - E. coli culture with the addition of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide.

[0182] Fig. 25 shows

[0183] A: Electron micrograph showing biofilm formation by E. coli isolate GIMC1404:EC-33P55 after 24 h (1), 48 h (2), and 72 h (3). B: Electron micrograph showing exopolysaccharide matrix accumulation by biofilm of coli isolate GIMC1404:EC-33P55 after 24 h (1), 48 h (2), and 72 h (3). C: Electron micrograph showing the effect of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide on E. coli GIMC1404:EC-33P55 biofilm formation after 24 h (1), 48 h (2), and 72 h (3).

[0184] D: Electron micrograph showing the effect of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide on exopolysaccharide matrix production by E. coli GIMC1404:EC-33P55 biofilm after 24 h (1), 48 h (2), and 72 h (3).

[0185] E: Graph showing biofilm formation by E. coli isolate GIMC1404:EC-33P55 after 24 h (1), 48 h (2) and 72 h (3).

[0186] The abscissa axis is the growth time of the bacterial culture, hours.

[0187] The y-axis is biofilm growth (OP540).

[0188] F: Graph showing the accumulation of exopolysaccharide matrix by the biofilm of E. coli isolate GIMC1404:EC-33P55 after 24 h (1), 48 h (2), and 72 h (3).

[0189] The abscissa axis is the growth time of the bacterial culture, hours.

[0190] The y-axis is biofilm growth (OP492).

[0191] G: Graph showing the effect of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide on E. coli GIMC1404:EC-33P55 biofilm formation after 24 h (1), 48 h (2), and 72 h (3).

[0192] The abscissa axis is the growth time of the bacterial culture, hours.

[0193] Y-axis - biofilm growth (OP540)

[0194] Gray columns - control, E. coli culture without the addition of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide

[0195] Columns filled with checkerboard pattern - E. coli culture with the addition of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide.

[0196] H: Graph showing the effect of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide on exopolysaccharide matrix production by E. coli GIMC1404:EC-33P55 biofilm after 24 h (1), 48 h (2) and 72 h (3).

[0197] The abscissa axis is the growth time of the bacterial culture, hours. The ordinate axis is the growth of biofilms (OP492)

[0198] Gray columns - control, E. coli culture without the addition of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide

[0199] Columns filled with checkerboard pattern - E. coli culture with the addition of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide.

[0200] Fig. 26 shows the results of the evaluation of the effectiveness of FC5 therapy in the Chlamydia trachomatis infection model.

[0201] X-axis - experimental groups

[0202] The ordinate axis is the number of bacteria in the smear (CFU)

[0203] Implementation of the invention.

[0204] A key aspect of developing a pharmaceutical substance is ensuring the bioavailability of the drug. Bioavailability characterizes the extent and rate at which the active substance (the parent drug or its metabolite) enters the systemic circulation, thereby reaching the site of action [MSD Manual. Professional Edition. [Electronic resource]. URL:

[0205]

[0206] bioavailability].

[0207] Increasing the bioavailability of the active substance may lead to the possibility of achieving a therapeutic effect at lower concentrations and, as a consequence, to a reduction in the daily dose of the drug, a decrease in the frequency of administration and a simplification of the application procedure (for example, by reducing the size of the tablets), as well as to a reduction in the risk of adverse reactions.

[0208] 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide is an inhibitor of the type III secretion system of pathogenic bacteria, which determines its effectiveness for the treatment and prevention of various infectious diseases.

[0209] During the production of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)carboxamide, crystals of various sizes are obtained. Large crystals (approximately 160 µm in size) have been shown to dissolve slowly in water. High solubility is critical for pharmaceutical compositions intended for oral administration.

[0210] Therefore, in early studies of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide and compositions based on it (including the prototype), a technology for obtaining the compound was used that included a sieving step through a sieve with a pore size of 50 μm (particle size was not additionally controlled). Thus, the resulting pharmaceutical substance had all particles smaller than 50 μm. This made it possible to achieve acceptable dissolution rates for the pharmaceutical composition obtained on the basis of this substance (in a 4% sodium lauryl sulfate (SLS) solution, at least 75% of the declared content of the active substance passes into solution within 45 minutes).

[0211] The first batches of the pharmaceutical substance 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide were prepared in small quantities. When scaling up the technology, it was decided to replace the sieving step with a milling step. The authors unexpectedly discovered that the bioavailability of the pharmaceutical substance increased dramatically. The results of the studies showed that the factor determining the bioavailability of the pharmaceutical substance is not the upper limit of particle size (50 μm in the prototype), but their modal size (the particle diameter corresponding to the maximum distribution density).

[0212] The modal particle size is the volumetric particle size that corresponds to the maximum of the particle distribution density [V.A. Arkhipov, A.S. Usanina. Movement of Dispersed Phase Particles in a Carrier Medium. Study Guide. Publishing House of Tomsk State University. Tomsk, 2014]. In other words, the modal size is the most frequently occurring value that corresponds to the peak on the size distribution curve. The authors found that the modal particle size of the pharmaceutical substance 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide is the most important characteristic on which the biological activity of the pharmaceutical substance depends.Thus, a pharmaceutical substance in which the modal particle size is 1 μm (that is, the peak of the distribution curve is at 1 μm) will have higher bioavailability than a substance in which the modal particle size is 10 μm (the peak of the distribution curve is at 10 μm), regardless of the sizes of the other particles.

[0213] The modal particle size of the prototype was found to be 48.0 µm. In later batches, the modal particle size was less than 45.9 µm. The study results showed that reducing the modal particle size of the pharmaceutical substance leads to increased bioavailability and an improved pharmacokinetic profile of the finished dosage form.

[0214] Conducted scientific studies have shown that an increase in the number of smaller 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide particles led to an increase in the surface area and accelerated dissolution of this compound in body fluids. In addition, a larger specific surface area allowed for higher adhesion and interaction with cell membranes for cellular absorption. Ultimately, all these facts influenced the rate and extent of absorption of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide, which are of primary importance for ensuring drug bioavailability in the human body.It should also be noted that despite the increase in bioavailability of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide, the toxicity of the pharmaceutical substance remained at an acceptable level (the pharmaceutical substance has a favorable safety profile). The results obtained during the study were confirmed for both crystalline and amorphous forms of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide.

[0215] It should be noted that selecting the optimal particle size for an active substance is a complex scientific task. Particle size not only affects the therapeutic activity of a drug but can also contribute to increased toxicity, the occurrence of side effects due to effective absorption, and increased peak concentrations in biofluids. Furthermore, drug particle size is of great importance for dosage form development, as it affects dosing uniformity and stability. Particle size also influences the behavior of materials during such important technological processes as compression, coating, and granulation, ultimately affecting the quality and characteristics of the final product. I. I. Krasnyuk et al. in their book [I. I. Krasnyuk, N. B. Demina, M. N. Anurova, N. L. Solovyova. Biopharmacy, or the Fundamentals of Pharmaceutical Development, Production, and Justification of Dosage Form Design. GEOTAR-Media, 2019].] provide several examples of how changes in particle size can impact drug production and quality in different ways. For example, only a finely crystalline substance is required to produce aminalone core tablets, while aminalone crystals measuring 500-1000 µm produce fragile, friable tablets. A good-quality carbamazepine tablet formulation can be produced by fluidized-bed granulation from a micronized substance (up to 20 µm), while traditional wet granulation requires a powder with a particle size of 50 to 300 µm. Pyrazinamide tablets are produced from a substance with a particle size of 100 to 300 µm. If a finely crystalline substance (up to 50 µm) is used, the resulting formulation does not meet the regulatory requirements for the dissolution test, as it is too strong.

[0216] The authors would also like to highlight several important points regarding the novelty of the claimed invention. Patent RU2743927C1 discloses a solid dispersion for the manufacture of dosage forms containing the active ingredient 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide (FT, CL-55, fluorothiazinone). Fig. 1 (RU2743927C1) shows the results of X-ray phase analysis of a sample of the active ingredient fluorothiazinone in crystalline form. The presented diffraction pattern allows one to estimate the average crystallite size in the analyzed substance. The calculation was performed using the Scherrer formula:

[0217] Dp = (0.94 x X) / ( x CosO), where

[0218] Dp = average crystallite size, = line broadening in radians, 0 = Bragg angle, X = X-ray wavelength.

[0219] The average crystallite size of the analyzed fluorothiazinone substance was determined to be 84.53 µm.

[0220] Fig. 11 (RU2743927C1) shows scanning electron microscopy micrographs of samples of the active substance fluorothiazinone in the crystalline phase. The authors would like to note that the technical objective of patent RU2743927C1 was to increase the bioavailability of the active substance. This objective was achieved by converting the substance into an amorphous state using polymers. To confirm the production of an amorphous substance, a series of micrographs were taken: of the active substance in the crystalline state (Fig. 11), the polymer (Fig. 12), and the solid dispersion (Fig. 13). To enable comparison of the micrographs, they were taken at the same magnification, and areas containing small crystallites were deliberately selected for shooting (the objective was not to measure the particle size, but to distinguish between the crystalline and amorphous phases of the substance). Therefore, the provided photograph (Fig. 11) does not allow one to estimate the average crystallite size in the active substance sample.The particle shown in the photograph may not significantly contribute to the biological activity of Fluorothiazinone, as the average particle size of the substance is known to be 84.53 µm, and the modal particle size has not been determined. However, RU2743927C1 indicates that the crystalline active substance had poor bioavailability, further confirming that the substance consisted primarily of large particles. Comparing the pharmacokinetic profiles of the substances also clearly shows that all pharmacokinetic parameters for the developed pharmaceutical substance significantly exceed those for the crystalline active substance described in RU2743927C1, indicating that it has higher bioavailability.The authors would also like to point out that not a single example concerning the use of fluorothiazinone for the treatment of chronic respiratory infections uses the active substance in the crystalline phase (only in the form of a solid dispersion with a polymer - in the amorphous phase), which is reflected in the titles of the examples and in the conclusions.

[0221] Furthermore, the authors would like to point out that scanning electron microscopy is generally unsuitable for particle size determination. A micrograph is a two-dimensional projection of a three-dimensional particle onto a plane. Therefore, it is only possible to estimate the particle's projected size. However, the researcher must manually set the points at which the size will be determined, resulting in a significant measurement error.

[0222] The prior art also includes patent RU2785195C1, which cites document RU2743927C1, and RU2785195C1 states: "Fig. 11 shows a photograph obtained during a study of the active substance in crystalline form using scanning electron microscopy, demonstrating that the powder contains parallelepiped-shaped particles with dimensions close to 12><8x5 μm (the aspect ratio is 2.4: 1.6: 1)." The authors would like to clarify that in this case, particle size refers to the size of the particle's projection onto a plane. This was acceptable for this work, since the objective was not to determine the true dimensions of the active substance crystallites, but only to determine their aspect ratio for comparison with other crystals: "the crystal of the form known from RU 2743927 has an elongated shape with a length-to-width ratio of approximately 2.4: 1. The crystal of the comparison sample is even more elongated (length to width ratio of about 6:1).Since both crystallite sizes were determined from photographs, it was assumed that the particles had the same aspect ratio as their projections. The authors would also like to clarify that reference RU2785195C1 does not confirm the use of the active substance with the stated particle size in any of its examples.

[0223] The present invention is implemented in the following manner: in the first stage, the active substance 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide is obtained in a crystalline or amorphous state, which is subsequently ground until a particle size distribution is achieved in which the modal particle size is less than 45.9 μm.

[0224] The resulting pharmaceutical substance is used to produce various pharmaceutical compositions and dosage forms. Finished dosage forms may include: aerosol, spray, inhalation powder, infusion solution, rectal or vaginal suppositories, oral powder, suspension, tablets, capsules, ointments, ointment dressings, gels, creams, eye ointments, eye gels, and eye creams. These dosage forms are used for oral, parenteral, intravenous, intramuscular, intranasal, rectal, intravaginal, and topical administration.

[0225] The studies have shown that the excipients used in these dosage forms, in particular, solvents (polyethylene glycol 300 (PEG 300), propylene glycol (PG), etc.), suppository base (cocoa butter, solid fat type A, solid fat type B, synthetic suppository bases: Witepsol H series, Witepsol W series, Witepsol S series, Butirol, etc.), fillers (lactose, microcrystalline cellulose, starch, sodium hydrogen carbonate, methylcellulose, silylated microcrystalline cellulose, sodium carboxymethyl cellulose, calcium carbonate, dibasic calcium phosphate, glycine, dextrin, amylol pectin, sorbitol, mannitol, pectin, etc.), anti-caking agents (silicates, aluminosilicates, magnesium and calcium carbonates, magnesium phosphates and calcium, magnesium oxide, silicon dioxide, ferrocyanides, cellulose), the basis for soft dosage forms (lanolin, petroleum jelly, etc.); absorption activators (ethyl and isopropyl alcohol, PEG 200-600, propylene glycol, dimethyl sulfoxide, etc.), stabilizers (gelatose, tween-80, starch, methylcellulose, etc.), solvents: dimethyl sulfoxide (dimexide), etc.; surfactants: polysorbates (tweens), etc.; propellants (liquefied gases, compressed gases and halogenated hydrocarbons or their mixtures) do not impair the antibacterial action of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide. In addition to the substances listed above, auxiliary substances of other classes can also be used in finished dosage forms to ensure acceptable technological properties.

[0226] As part of this work, an antibacterial pharmaceutical composition was created containing the developed pharmaceutical substance and pharmaceutically acceptable excipients. The resulting composition can be used in powder form or used to create a finished dosage form—a tablet.

[0227] Table 1. Composition of the pharmaceutical composition.

[0228]

[0229] The use of excipients in the pharmaceutical composition makes it possible to manufacture a finished dosage form with acceptable characteristics.

[0230] The following classes of excipients are known:

[0231] 1) Fillers - substances used to impart a certain mass to the dosage form, facilitate rapid disintegration, and ensure compressibility. The following can be used as fillers: lactose, microcrystalline cellulose, starch, sodium bicarbonate, methylcellulose, silicified microcrystalline cellulose, sodium carboxymethyl cellulose, calcium carbonate, dibasic calcium phosphate, glycine, dextrin, amylopectin, sorbitol, mannitol, pectin, etc., or mixtures thereof. 2) Surface modifiers - hydrophilic surfactants or polymers that reduce the surface tension of water are used as surface modifiers. These excipients are used to reduce the loss of the active substance at subsequent stages and to ensure uniform distribution of the active substance in the granulate.

[0232] 3) Binders enhance the mutual adhesion of individual particles and ensure the transition of the powdered substance into granules, determine the technological properties of the granulate (in particular, homogeneity and flowability, which correlates with dosing accuracy), and ensure the strength of the granules. The following can be used as binders: Kollicoat IR (Kollicoat IR), polyvinyl alcohol, polyvinyl pyrrolidone, polyethylene glycol, hyprolose, low-substituted hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, etc., or mixtures thereof.

[0233] 4) Disintegrants improve the disintegration of solid dosage forms in the gastrointestinal tract and the release of the active ingredient. Disintegrants that can be used include starch, sodium starch glycolate, carboxymethyl starch, crospovidone, aerosil, sodium lauryl sulfate, talc, sodium croscarmellose, and others, or mixtures thereof.

[0234] 5) Lubricants reduce friction between granulate particles and pharmaceutical equipment, reduce adhesion, and prevent granulate from sticking to equipment surfaces. Stearic acid, calcium and magnesium stearate, and others can be used as lubricants.

[0235] The pharmaceutical composition may include excipients of other classes to ensure acceptable processing properties of the granulated mass for producing a solid dosage form. An acceptable coating may also be used to coat the tablet or components of the finished dosage form.

[0236] The developed pharmaceutical composition is used for antibacterial therapy. In particular, antibacterial therapy is carried out against pathogenic (e.g., Staphylococcus aureus) or opportunistic bacteria (e.g., Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae). Antibacterial therapy is also carried out against bacteria with an extracellular type of parasitism (e.g., P. aeruginosa, E. coli) or an intracellular type of parasitism (e.g., Chlamydia spp.). In addition, antibacterial therapy is carried out against bacteria that cause acute infections (Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii) or chronic infections (Chlamydia trachomatis, E. coli). In another case, antibacterial therapy is carried out against bacteria that cause recurrent diseases (e.g., uropathogenic E. coli).An application of the pharmaceutical composition has been developed in which it is administered simultaneously with an antibiotic or used as monotherapy (example 16).

[0237] In another embodiment, the pharmaceutical composition is used for the prevention of nosocomial infection (example 12).

[0238] One application of the pharmaceutical composition is through inhibition of biofilm growth (examples 18, 19). Another application is through reduction of bacterial motility (example 15). Another application is through reduction of bacterial virulence (example 13).

[0239] The developed pharmaceutical composition is administered to mammals at doses containing active ingredient ranging from 1 mg to 12,600 mg. Currently, a tablet form of the pharmaceutical composition has been developed containing 300 mg, 600 mg, or 1,200 mg of the active ingredient. The dose and frequency of administration are determined by the physician based on the patient's weight, the etiology and severity of the disease, medical history, and additional therapy.

[0240] In the context of this invention, the dose of a pharmaceutical composition is equal to the dose of the active ingredient in that composition. For example, if it is stated that volunteers received a pharmaceutical composition at a dose of 600 mg, this means that the volunteers received a pharmaceutical composition at a dose containing 600 mg of the active ingredient.

[0241] The implementation of the invention is confirmed by the following examples.

[0242] Example 1. Preparation of a crystalline form of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide. The general approach to the synthesis of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide VIII (compound CL-55) is shown in Fig. 1.

[0243] Synthesis of 2-chloro-N-(2,4-Difluorophenyl)-acetamide (III)

[0244] To a solution of 2,000 g of 2,4-difluoroaniline (I) in 2,000 ml of DMF, 1955 g of chloroacetyl chloride (II) are added with stirring and cooling, ensuring that the temperature of the reaction mixture does not exceed 20 °C. After the addition of chloroacetyl chloride (II) is complete, the solution is stirred at room temperature for another 2 hours. Then 4,000 ml of purified water are added to the reaction mixture and the formed precipitate is filtered off. It is washed on the filter with water and dried in a vacuum desiccator. The yield of acetamide (III) is 2,760 g (87%).

[0245] Synthesis of 2-morpholin-4-yl-2-thioxo-N-(2,4-difluorophenyl)acetamide (IV) A suspension of 1410 g of elemental sulfur in 8000 ml of DMF is preliminarily prepared with stirring and 3840 g of morpholine is added. The resulting mixture is stirred and a solution of 2760 g of chloroacetamide(III) in 4000 ml of DMF is added to the resulting suspension while cooling to 0-20 °C. The reaction mixture is then poured into water, the precipitated crystals are filtered off and washed on a filter with water. Then the resulting precipitate is redissolved in acetone with stirring and unreacted sulfur is filtered off. The organic solvent is separated, acetone is evaporated, and 2800 g (73%) of morpholide(I) crystals are obtained.

[0246] Synthesis of 2-hydrazino-2-thioxo-N-(2,4-difluorophenyl)-acetamide (V)

[0247] The resulting morpholide (V) (2800 g) is dissolved in 8000 ml of dimethylformamide, and 1000 g of hydrazine hydrate is added with stirring at room temperature. The solution is then poured into water and acidified with hydrochloric acid to a pH of 6-7. The resulting precipitate is filtered and dried in an oven at 50°C. The yield of hydrazine (V) is 1890 g (83%).

[0248] Synthesis of 2-[N'-(3-ethoxy-4-hydroxy-benzylidene)-hydrazino]-2-thioxo-N-(2,4-difluorophenyl)-acetamide (VI)

[0249] To 1890 g of 2-hydrazino-2-thioxo-N-(2,4-difluorophenyl)-acetamide (V) in 8000 ml of dimethylformamide are added 1362 g of 3-ethoxy-4-hydroxybenzaldehyde and stirred at room temperature for 5 hours. Water is added to the reaction mixture and 2350 g (76%) of 2-[N'-(3-ethoxy-4-hydroxybenzylidene)-hydrazino]-2-thioxo-N-(2,4-difluorophenyl)-acetamide (VI) crystals are filtered off, washed on a filter with isopropyl alcohol, and dried in a drying oven at 50 °C.

[0250] Synthesis of 2-[N'-(3-ethoxy-4-hydroxy-benzyl)-hydrazino]-2-THOKCO-N-(2,4-difluoro-phenyl)-acetamide(UP)

[0251] With cooling (0 - 10 °C) and stirring, 257 g of sodium borohydride is added to a suspension of 2350 g of 2-[N'-(3-ethoxy-4-hydroxy-benzylidene)-hydrazino]-2-thioxo--(2,4-difluorophenyl)-acetamide in methanol in small portions, not allowing its temperature to rise above 15 °C. Then 30 l of water are added. The resulting solution is acidified with hydrochloric acid to pH 6-7. The formed precipitate is filtered off and recrystallized from isopropanol. Yield (VII) - 1890 g (80%).

[0252] Synthesis of 4-(3-ethoxy-4-hydroxy-benzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-carboxy-(2,4-difluorophenyl)amide.

[0253] To obtain the crude substance 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-carboxy-(2,4-difluorophenyl)amide, 1890 g of 2-[N'-(3-ethoxy-4-hydroxybenzyl)hydrazino]-2-thioxo-N-(2,4-difluorophenyl)acetamide is added to a solution of 520 g of chloroacetic acid in 8000 ml of isopropyl alcohol while stirring. Then 462 g of ammonium acetate are added to the reaction mixture and the mixture is boiled at a temperature of 80 - 82 °C for 5-7 hours. After the reaction is complete, the reaction mixture is cooled to 20-25°C, the precipitated crystals are filtered off, and washed on the filter with purified water and isopropyl alcohol. The yield of the crude substance is 1566 g, or 75%.

[0254] The resulting product is purified by recrystallization from isopropyl alcohol. The purified substance is white crystals with a melting point of 134–135°C. In this manner, the crystalline form of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide was obtained.

[0255] Example 2. Obtaining an amorphous form of the active pharmaceutical substance 4-(3-ethoxy-4-hydroxy-benzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-carboxy-(2,4-difluorophenyl)amide.

[0256] The active substance is 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide (CL-55), may be contained in any morphological form: both in crystalline or amorphous form, and in amorphous form with an admixture of microcrystalline and crystalline phase; Obtaining the crystalline form of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide is achieved by recrystallization of the crude finished product in a primary or secondary aliphatic lower alcohol containing 2-4 carbon atoms, or in a mixture of such alcohols upon heating. Crystalline 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)carboxamide precipitates upon slow cooling. The procedure for obtaining the crystalline form of the active pharmaceutical ingredient is described in Example 1.

[0257] Unlike the crystalline form of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide, the preparation of its amorphous form is carried out by precipitation of the dissolved substance from the solution using a precipitating solvent.

[0258] The process of preparing amorphous 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide is carried out by precipitating it using a solvent in which 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide is not soluble or is very slightly soluble, from a solution of crystalline 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in a solvent in which it is readily soluble. Preferred solvents in which 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide is readily soluble include, for example, dimethyl sulfoxide, dimethylformamide or tetrahydrofuran.

[0259] Thus, an amorphous form of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide was obtained.

[0260] Example 3. Obtaining a pharmaceutical substance with increased bioavailability.

[0261] The pharmaceutical substance is 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide (may be in crystalline form, amorphous form, or in amorphous form with an admixture of microcrystalline and crystalline phases), which is ground to a state in which the modal particle size of the substance is less than or equal to 45.9 μm. This example describes a method for producing a pharmaceutical substance that involves grinding using a benchtop knife mill. However, it is obvious to a person of ordinary skill in the art that any grinding device that allows achieving the appropriate particle size of the pharmaceutical substance can be used in this case (e.g., a ball mill, a continuous cutting mill, a disc mill, a planetary mill, a vibration mill, a three-roll mill, etc.).

[0262] As an example, we can cite the following method for obtaining a pharmaceutical substance:

[0263] Approximately 300–350 g of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide powder was loaded into the bowl of a knife mill and ground at a knife speed of 26,000 rpm with constant bowl cooling for one minute. The operation was repeated nine more times with a 30-minute interval between each iteration.

[0264] Particle size was measured using a Bettersizer 2600 and Zetasizer. Figures 2–5 show the particle size results for the pharmaceutical substance after grinding for 2 min, 4 min, 6 min, and 10 min.

[0265] The modal particle size (Mode) was defined as the particle diameter corresponding to the maximum of the particle size distribution density (Table 2).

[0266] Table 2. Modal particle size in different variants of the pharmaceutical substance

[0267]

[0268] The conducted studies showed that the modal particle size of the pharmaceutical substance ground for 2 minutes was as close as possible to the prototype. As the grinding time increased, the modal particle size decreased. The minimum modal particle size given in this example was 7.1 μm. However, it is obvious to a person of average skill that by increasing the mill speed or grinding time, the modal particle size can be reduced. Figure 5 shows that the sample ground for 10 minutes contains a large number of 0.7 μm particles. As the grinding time increases, the fraction of these particles increases until the modal particle size in the sample reaches 0.7 μm.

[0269] Thus, as a result of the work carried out, variants of the pharmaceutical substance with a modal particle size less than or equal to 45.9 µm were obtained.

[0270] Example 4. Obtaining a pharmaceutical composition containing 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide.

[0271] Preliminary studies have shown that changes in the composition and ratios of excipients within the range of values ​​indicated in Table 3 do not have a significant effect on the bioavailability of the active substance.

[0272] Table 3. Composition of the pharmaceutical composition.

[0273]

[0274] This example describes a variant of manufacturing a pharmaceutical composition that had the composition presented in Table 4.

[0275] Table 4. Composition of the pharmaceutical composition.

[0276]

[0277]

[0278] Three versions of the pharmaceutical composition were produced, using a pharmaceutical substance containing particles of different sizes:

[0279] 1) FK1 - 45.9 µm

[0280] 2) FK2 - 10.0 µm

[0281] 3) FKZ - 7.1 µm

[0282] The obtained variants of the pharmaceutical composition were used to obtain the finished dosage form powder.

[0283] The required amount of substances for the preparation of 1 batch of tablets was weighed on a scale, a humectant solution containing sodium lauryl sulfate, polyvinyl alcohol, and polyethyleneglycol was prepared. Next, the crushed substance 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide, with granular microcrystalline cellulose inside, was loaded into a fluidized bed granulator dryer. The air flow was turned on and the product was heated to a bed temperature of 40°C. Upon reaching the temperature, a humectant spraying stage was performed, and the resulting granulate was dried to a bed temperature of 55°C. Upon reaching the bed temperature, the drying process was stopped and the granulate was unloaded.

[0284] The unloaded dry granulate was calibrated on a sieve with a mesh size of 0.8 mm. The calibrated dry granulate was transferred to a mixer, lactose monohydrate, sodium starch glycolate, and microcrystalline cellulose were added, mixed for a specified time, then magnesium stearate was added as a lubricant and mixed again.

[0285] The obtained variants of the pharmaceutical composition were used to produce the finished dosage form of a tablet.

[0286] The tablet form was obtained by granulation in a fluidized bed.

[0287] The required amount of substances for the preparation of 1 batch of tablets was weighed on a scale, a humectant solution containing sodium lauryl sulfate, polyvinyl alcohol, and polyethyleneglycol was prepared. Next, the crushed substance 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide, with granular microcrystalline cellulose inside, was loaded into a fluidized bed granulator dryer. The air flow was turned on, the product was heated to a bed temperature of 40°C. Upon reaching the temperature, a humectant spraying stage was carried out, and the resulting granulate was dried to a bed temperature of 55°C. Upon reaching the bed temperature, the drying process was stopped and the granulate was unloaded.

[0288] The unloaded dry granulate was calibrated on a 0.8 mm sieve. The calibrated dry granulate was transferred to a mixer, lactose monohydrate, sodium starch glycolate, and microcrystalline cellulose were added, and mixed for the specified time. Magnesium stearate was then added as a lubricant and mixed again. The resulting tablet mass was discharged into a collection bin and sent to the tableting stage.

[0289] As a result of the work carried out, 4 variants of the finished dosage form powder were obtained, as well as 4 variants of the finished dosage form tablets based on variants of the pharmaceutical substance containing a pharmaceutical substance with different particle sizes.

[0290] Example 5. Assessing the bioavailability of developed pharmaceutical substance variants. Before entering the bloodstream, the drug must be released from the dosage form and dissolve in the biofluid. Therefore, solubility is an important indicator of bioavailability.

[0291] The dissolution test is one of the key analytical tests for all solid dosage forms (DF) for internal use. This test allows one to determine the rate and extent of active substance release into the dissolution medium from a solid dosage form under standardized conditions, which to some extent simulates the behavior of the DF in the human gastrointestinal tract [Ignatyeva E.V., Shprakh Z.S., Yartseva I.V., Sanarova E.V. Dissolution test as an element of a comprehensive quality assessment of capsules containing secoisolariciresinol. Russian Journal of Biotherapeutics. 2019; 18(1):95-100.]. The definition of this indicator is standardized and set out in the General Pharmacopoeia Monograph "Dissolution for Solid Dosage Forms".The pharmacopoeial monograph states that the amount of active substance released into the dissolution medium from each unit of the dosage form within 45 minutes must be at least 80% of the declared content (Q + 5%), where Q is the amount of active substance released from the unit of the dosage form into the dissolution medium over a specified period of time, expressed as a percentage of the declared content. The Q value is considered to be equal to 75%.

[0292] In this experiment, the test was conducted using two dissolution media: 4% sodium lauryl sulfate (SLS), which was described in the prototype, or a 2% sodium lauryl sulfate (SLS) solution. The more soluble the substance, the less detergent (SLS) was needed to achieve acceptable dissolution rates.

[0293] Dissolution conditions

[0294] Apparatus: "Bed mixer"

[0295] Dissolution medium:

[0296] 4% sodium lauryl sulfate solution (4% SLS);

[0297] 2% sodium lauryl sulfate solution (2% SLS);

[0298] Volume of dissolution medium: 1000 ml

[0299] Stirrer speed: 100 rpm Dissolution medium temperature: (37 ± 0.5) °C

[0300] Dissolution time: 60 minutes

[0301] Preparation of solutions

[0302] Dissolution medium:

[0303] 1) 4% SLS solution

[0304] 40 g of sodium lauryl sulfate is placed in a 1000 ml measuring flask, dissolved in water using a magnetic stirrer, the volume of the solution is brought up to the mark with water and stirred, after removing the magnetic stirrer.

[0305] 2) 2% SLS solution

[0306] 20 g of sodium lauryl sulfate is placed in a 1000 ml measuring flask, dissolved in water using a magnetic stirrer, the volume of the solution is brought up to the mark with water and stirred, after removing the magnetic stirrer.

[0307] Standard solution

[0308] About 30 mg of the standard sample of the active substance is placed in a 100 ml measuring flask, 50 ml of acetonitrile is added and treated in an ultrasonic bath for 10 minutes or until completely dissolved, cooled to room temperature and the volume of the solution is brought up to the mark with the dissolution medium and mixed (the concentration of the active substance is about 0.3 mg / ml).

[0309] Test solution

[0310] One tablet containing the pharmaceutical composition is placed in each of twelve dissolution vessels containing 1000 ml of dissolution medium thermostatted at 37 ± 0.5 °C. Stirring is started, and a 5 ml sample is taken from the center of the vessel at 15, 30, 45, and 60 minutes after the start of the study. The sample is filtered through a nylon membrane syringe filter with a pore diameter of 0.45 μm, discarding the first 2 ml of the filtrate (active ingredient concentration approximately 0.3 mg / ml).

[0311] Chromatographic conditions

[0312] Column: BDS HYPERSIL Thermo Cl 8 50 * 4.6 mm 5 μm; Mobile phase: PF A 50: 50 PF B; Flow rate: 1 ml / min;

[0313] Column temperature: 30 °C;

[0314] Wavelength: 280 nm;

[0315] Injection volume: 5 µl;

[0316] Chromatography time: 4 minutes

[0317] The amount of active substance transferred into solution (X), as a percentage of the declared amount, is calculated using the formula:

[0318] Si x a0x 1000 x P x 100

[0319]

[0320] 50x100xL

[0321] Where:

[0322] Sj is the peak area of ​​the active substance on the chromatogram of the test solution; So is the peak area of ​​the active substance on the chromatogram of the standard solution; ao is the sample weight of the active substance, mg;

[0323] L — the declared amount of active substance in a tablet, mg;

[0324] P is the content of the active substance in the active substance solution, mg / mg.

[0325] Tables 5-6 show the results of a comparative test of the dissolution kinetics of tablets containing different versions of the pharmaceutical composition.

[0326] Fig. 6 shows the average dissolution profile of tablets containing different versions of the pharmaceutical composition compared to the prototype in a 4% SLS solution.

[0327] Fig. 7 shows the average dissolution profile of tablets containing variants of the pharmaceutical composition compared to the prototype in a 2% SLS solution. Table 5 - Results of a comparative test of the dissolution kinetics of tablets containing FC2 and FC1. Dissolution medium: 4% sodium dodecyl sulfate solution.

[0328]

[0329] Table 6 - Results of a comparative test of the dissolution kinetics of tablets containing FK2 and FK1. Dissolution medium: 2% sodium dodecyl sulfate solution.

[0330]

[0331] As can be seen from the presented data, the pharmaceutical composition containing particles that have a modal size of 45.9 μm demonstrates a dissolution curve similar to the dissolution curve of the pharmaceutical composition described in the prototype, while variants of the pharmaceutical composition having a modal particle size of less than 45.9 μm demonstrate a higher rate and degree of release of the active substance into the dissolution medium from the solid dosage form.

[0332] Thus, the experimental results show that the developed pharmaceutical substance has better bioavailability indicators compared to the prototype.

[0333] Example 6. Study of the pharmacokinetics of the developed pharmaceutical composition in rats.

[0334] The aim of this experiment was to investigate the pharmacokinetic parameters of the developed pharmaceutical composition with improved bioavailability compared to the prototype. The following pharmaceutical compositions were used for this experiment:

[0335] 1) prototype

[0336] 2) a variant of the pharmaceutical composition in which the particles of the pharmaceutical substance had a modal size of 10.01 μm (FC2).

[0337] To study the pharmacokinetics of the active substance and its metabolite after administration of the developed pharmaceutical composition (or prototype), 12 Wistar rats weighing 220-250 g were used. The rats were administered an aqueous suspension of the tablet intragastrically at a dose of 50 mg / kg. Blood for analysis was collected from the rats at the following time points: 0 h (before administration), 0.5 h, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h, 36 h, 48 h. Quantitative determination of the active substance and its metabolite was performed by high-performance liquid chromatography with tandem mass spectrometric detection (HPLC-MS / MS) according to a validated method. Compound concentrations were calculated using an internal standard.

[0338] The pharmacokinetic parameters (Table 7) were calculated using Phoenix WinNonLin 8.3 software (Version 8.3.4.295, Certara, USA) using a model-independent method based on the active substance concentrations measured in biological samples. The experimental results are presented in Tables 8-9.

[0339] Table 7. Parameters for assessing the pharmacokinetics of the active substance and its metabolite.

[0340] <

[0341]

[0342] Table 8. Pharmacokinetic parameters of the active substance and its metabolite after administration of the prototype at a dose of 50 mg / kg.

[0343]

[0344]

[0345] Table 9. Pharmacokinetic parameters of the active substance and its metabolite after administration of the developed pharmaceutical composition (with a modal particle diameter of the pharmaceutical substance of 10.01 μm) at a dose of 50 mg / kg.

[0346]

[0347] Following oral administration of the prototype to rats at a dose of 50 mg / kg, the substance was detectable in the blood throughout the entire observation period (48 hours). The half-elimination period was 45.5 ± 3.5 hours, and the mean residence time (MRT) was 19.64 ± 7.1 hours, indicating a long presence of the test substance in the systemic circulation of animals. The maximum concentration (Cmax) in blood plasma was recorded 0.5 ± 3.8 hours (Tmax) after administration of the substance, and its value was 4.97 ± 5.4 ng / ml. AUC0— t is reached at 47.94 ± 45.8 ng / ml*h. Glucuronide of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide is detected in the blood throughout the entire observation period (48 h). The half-elimination period was 6.05 ± 7.5 h, the mean residence time of the substance in the body (MRT) was 9.40 ± 8.7 h, indicating a long-term presence of the test substance in the systemic circulation of animals.The maximum concentration (Cmax) in blood plasma was recorded 0.5 ± 2.3 (Tgpax) after administration of the drug, and its value was 30.92 ± 13.9 ng / ml. AUC0—>t is reached 198.21 ± 78.9 ng / ml*h.

[0348] Following oral administration of a pharmaceutical composition variant containing 10.01 μm modal particle size of the pharmaceutical substance to rats at a dose of 50 mg / kg, the substance was detectable in the blood throughout the entire observation period (48 h). The elimination half-life was 10.51 ± 3.15 h, and the mean residence time (MRT) of 12.16 ± 3.19 h indicated prolonged presence of the test substance in the systemic circulation of animals. The maximum plasma concentration (Cmax) was recorded 1.33 ± 1.53 h (Tmax) after substance administration and was 11.2 ± 10.67 ng / ml. AUCO—>t was reached at 144 ± 60.6 ng / ml h. Glucuronide of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide is detected in the blood throughout the entire observation period (48 hours).The elimination half-life was 27.5 ± 1.76 h, and the mean residence time (MRT) was 11.7 ± 1.2 h, indicating a prolonged presence of the test substance in the systemic circulation of animals. The maximum concentration (Cmax) in blood plasma was recorded 2.17 ± 1.76 h (Tmax) after administration of the drug, and its value was 120 ± 25 ng / ml. AUCO— >t is reached at 586 ± 840 ng / ml h.

[0349] Table 10 shows the pharmacokinetic parameters of free 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide after oral administration of a variant of the pharmaceutical composition in which the particles of the pharmaceutical substance had a modal size of 10.01 μm, in comparison with the pharmacokinetic parameters of the pharmaceutical composition according to patent RU2737087C1 (prototype).

[0350] Table 10. Comparative pharmacokinetic parameters of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in rats after a single oral administration of the prototype or the developed pharmaceutical composition at a dose of 50 mg / kg

[0351]

[0352] ><

[0353]

[0354] It is clearly evident that all pharmacokinetic parameters of the developed pharmaceutical composition significantly exceed those of the prototype. The most significant bioavailability indicators, such as the maximum concentration of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide, achieved in the bloodstream for the developed pharmaceutical compositions, exceed the values ​​for the prototype by 2 and 3 times. Another significant indicator, the area under the pharmacokinetic curve, is also significantly higher for the developed composition, almost 3 times. Moreover, the half-life of free 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide for the developed composition is significantly shorter when compared with the prototype.This can be explained by a more efficient tissue distribution of the substance when using the developed pharmaceutical composition, as well as a possibly more efficient excretion of the substance from the bloodstream, limiting the undesirable cumulative effect.

[0355] The obtained pharmacokinetic profile results for the developed pharmaceutical composition indicate increased bioavailability compared to the prototype. These data can be explained by the lack of particle size control during the preparation of the pharmaceutical substance, as described in patent RU2737087. Thus, the developed pharmaceutical substance is characterized by greater bioavailability, indicating the achievement of the technical result.

[0356] Example 6. Obtaining a pharmaceutical composition containing various excipients.

[0357] Two formulation variants were manufactured, each with different excipients. The modal particle size of the active ingredient in both variants was 7.1 µm. One pharmaceutical formulation (FC4) had the composition shown in Table 11.

[0358] Table 11. Composition of pharmaceutical composition FK4.

[0359]

[0360]

[0361] In another embodiment, the pharmaceutical composition (FC5) had the composition presented in Table 12.

[0362] Table 12. Composition of pharmaceutical composition FK5.

[0363]

[0364]

[0365] The tablet form was obtained by granulation in a fluidized bed.

[0366] The required amount of substances for preparing 1 batch of tablets is weighed on a scale, a humectant solution containing sodium lauryl sulfate and Kollicoat IR is prepared (for the first version of the composition). In the second version of the composition, polyvinyl alcohol and polyethyleneglycol are added instead of Kollicoat IR. Next, the crushed substance 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide is loaded into a fluidized bed granulator dryer, with granular microcrystalline cellulose inside, the air flow is turned on, the product is heated to a bed temperature of 40°C, upon reaching the temperature, the humectant is sprayed (an aqueous suspension of sodium lauryl sulfate and Kollicoat IR), and the resulting granulate is dried to a bed temperature of 55°C. Once the temperature in the layer is reached, the drying process is stopped and the granulate is unloaded.

[0367] The discharged dry granulate is calibrated on a sieve with a mesh size of 0.8 mm.

[0368] The calibrated dry granulate is transferred to a mixer. Lactose monohydrate, sodium starch glycolate, and microcrystalline cellulose are added. Mix for the specified time. Magnesium stearate is then added as a lubricant and mixed again. The resulting tablet mass is discharged into a collection container and sent to the tableting stage. The resulting tablets are packaged in polymer jars or in blisters made of polyvinyl chloride film and aluminum foil. Example 7. Test to confirm the bioequivalence of various pharmaceutical composition formulations.

[0369] In this test, two variants of the pharmaceutical composition obtained in Example 3 were used:

[0370] 1) Pharmaceutical composition FK4;

[0371] 2) Pharmaceutical composition FK5.

[0372] To confirm the bioequivalence of various formulations of the pharmaceutical composition, a dissolution test was used (apparatus II “Paddle stirrer”): the amount of active substance released into the dissolution medium (4% sodium dodecyl sulfate solution) at a temperature of (37 ± 0.5) °C, for 45 minutes at a paddle stirrer rotation speed of 75 rpm was more than 75% (Q) of the declared content.

[0373] Preparation of solutions

[0374] Dissolution medium according to the ND project is 4% sodium dodecyl sulfate solution (4% SLS solution)

[0375] 40 g of sodium dodecyl sulfate is placed in a 1000 ml measuring flask, dissolved in water using a magnetic stirrer, the volume of the solution is brought up to the mark with water and stirred, after removing the magnetic stirrer.

[0376] Test solution

[0377] One tablet is placed in each of twelve dissolution vessels containing 1000 ml of dissolution medium thermostatted at a temperature of (37 ± 0.5) °C. Stirring is started, and 5 ml of a sample is taken from the center of the vessel after 15, 30, 45, and 60 minutes from the start of the study. The sample is filtered through a nylon membrane syringe filter with a pore diameter of 0.45 μm, discarding the first 2 ml of the filtrate (the concentration of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide (CL-55) is approximately 0.3 mg / ml).

[0378] Chromatographic conditions

[0379] Column: BDS HYPERSIL Thermo C18 50 * 4.6 mm 5 μm;

[0380] Mobile phase: PF A 50: 50 PF B;

[0381] Flow rate: 1 ml / min;

[0382] Column temperature: 30 °C; Wavelength: 280 nm;

[0383] Injection volume: 5 µl;

[0384] Time: 4 minutes

[0385] chromatography:

[0386] The amount of CL-55 transferred into solution (X), as a percentage of the declared amount, is calculated using the formula:

[0387] Si x a0x 1000 x P x 100

[0388]

[0389] S o x 100 x L

[0390] Where:

[0391] Si is the area of ​​the CL-55 peak on the chromatogram of the test solution;

[0392] S0 is the area of ​​the CL-55 peak on the chromatogram of the standard solution;

[0393] aO - sample weight of CO CL-55, mg;

[0394] L - the declared amount of CL-55 in a tablet, mg;

[0395] P – content of CL-55 in CO CL-55, mg / mg.

[0396] The results of the comparative dissolution kinetics test for FC4 and FC5 are presented in Table 13.

[0397] Table 13 - Results of a comparative test of the dissolution kinetics of the medicinal product and the reference medicinal product. The dissolution medium according to the draft regulatory document is a 4% sodium dodecyl sulfate solution.

[0398]

[0399]

[0400] The experimental results showed that when comparing two pharmaceutical compositions, the similarity factor was greater than 85%. This satisfies the acceptance criterion for a similarity factor, which should be between 50 and 100, confirming the comparability of the dissolution profiles.

[0401] Example 8. Study of the safety of a drug based on 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide with single and course administration at doses from 1200 to 2400 mg / day in healthy volunteers.

[0402] In this study, the tablet form of the pharmaceutical composition FK5 was used.

[0403] The aim of the study was to evaluate the safety of FC5 with high-dose daily use with dose escalation (in three dosages - 1200 mg, 1800 mg and 2400 mg), as well as with course use in healthy volunteers.

[0404] Exposure value

[0405] Group 1. Five volunteers received FC5 600 mg (2 tablets of 300 mg) twice at 12-hour intervals for 1 day (daily dose = total dose for the entire study period = 1200 mg).

[0406] Group 2. Five volunteers received FC5 at 900 mg (3 tablets of 300 mg) twice at 12-hour intervals for 1 day (daily dose = total dose for the entire study period = 1800 mg).

[0407] Group 3. Five volunteers received 1200 mg of FC5 (four 300 mg tablets) twice at 12-hour intervals for one day (daily dose = total dose for the entire study period = 2400 mg). In this group, one volunteer received only the morning dose of 1200 mg of PI because he developed vomiting and further PI administration was discontinued; for this volunteer, the total PI dose was 1200 mg.

[0408] Group 4. Fifteen volunteers received FC5 at a dose of 900 mg (3 tablets of 300 mg) twice with an interval of 12 hours for 7 days. The total dose for the entire study period = 1800 * 7 = 12600 mg. Any adverse events (AE) during the study were recorded in 1 / 5 of the volunteers in group 2 (one AE), in 1 / 5 of the volunteers in group 3 (one AE), and in 6 / 15 volunteers in group 4 (9 AE). Thus, the total number of AEs recorded in the study was 11. Table 14 shows the results of the adverse event assessment in volunteers by visit.

[0409] Table 14. Number of volunteers with AE by visits

[0410]

[0411] Data are presented as X (%) Y, where X (%) is the number of subjects with at least one event (percentage by column) and Y is the number of events.

[0412] All reported AEs were:

[0413] 1) gastrointestinal disorders: vomiting (1 AE) in group 3, gastritis (1 AE), diarrhea (1 AE), dyspepsia (1 AE) in group 4;

[0414] 2) disorders of the nervous system: headache (1 AE) in group 2; 3 AE in the form of headache and 1 AE “dizziness” in group 4.

[0415] 3) urethritis (1 AE), increased leukocyte count (1 AE) in group 4. A total of 3 AEs in group 4 (diarrhea and 2 cases of headache) and vomiting in group 3 were considered to be possibly related to the PI. The remaining AEs were of questionable relationship to the drug.

[0416] The study drug was discontinued due to the AE "vomiting" in group 3. In the remaining cases, the study drug was administered according to the protocol. All clinical AEs resolved; the outcome was marked "unknown" only for the AE of increased white blood cell count. Treatment was required for 4 AEs: vomiting in group 3, gastritis, headache, and urethritis in group 4. No treatment was required for the remaining AEs. No serious adverse events (SAEs), including deaths, other SAEs, or other significant AEs, were reported.

[0417] It can be noted that in the 7-day course group, the proportion of volunteers with any adverse event (6 / 15, 40%) was twice as high as in the groups of volunteers who took the study drug for one day at a daily dose of 1800 mg and 2400 mg (1 / 5, i.e.

[0418] 20% in each case). In the lowest daily dose group (1200 mg), there were no AEs. However, the proportion of volunteers with AEs related to the study drug was the same (20%) in Group 4 and Group 3, and no AEs related to the drug were observed in Group 2. All AEs reported were mild.

[0419] Thus, the results of the study suggest that FK5 is well tolerated when administered daily at high doses with escalating doses (in three dosages: 1200 mg, 1800 mg, and 2400 mg), as well as when administered as a course in healthy volunteers. Mild, non-serious adverse events were reported during the study, primarily gastrointestinal and nervous system disorders. In one case, treatment was discontinued due to vomiting after a single dose of 1200 mg. No serious adverse events (SAEs), including deaths, other SAEs, or other significant AEs, were reported. No abnormalities related to PI administration were observed in laboratory parameters, physical examination results, vital signs, or ECG.

[0420] Example 9. Study of the effect of a drug based on the developed pharmaceutical substance on intestinal microflora after a course of drug administration in healthy volunteers.

[0421] In this study, the tablet form of the pharmaceutical composition FC5 was used. The aim of the study was to evaluate the effect of FC5 on intestinal microflora during a course of treatment in healthy volunteers.

[0422] Fifteen volunteers received FC5 at a dose of 900 mg (3 tablets of 300 mg) twice, 12 hours apart, for 7 days. The total dose over the entire study period = 1800 x 7 = 12600 mg. Stool samples were collected from the volunteers for intestinal microflora analysis before the first dose of the study drug (IP) and again 7 days later (day 8).

[0423] The results were as follows:

[0424] Pathogenic Escherichia coli, Shigella, and Salmonella were not detected in all volunteers before and after the end of the course of IP administration.

[0425] Bifidobacteria, lactobacilli, clostridia, enterococci, typical Escherichia coli, non-fermenting bacteria, Staphylococcus saprophiticus, Staphylococcus epidermidis were detected in all volunteers before and after the end of the course of IP intake without deviations from the norm.

[0426] Lactose-negative Escherichia coli were detected in three volunteers before taking the IP and were eliminated after taking the IP. Lactose-negative Escherichia coli were detected in two volunteers after completing the course.

[0427] In 3 volunteers, elimination of the opportunistic pathogen Klebsiella pneumoniae was observed after a course of IP administration.

[0428] Non-hemolytic Staphylococcus aureus was detected in 4 (26.7%) volunteers in low titers (102 and 103) after a course of IP administration (it was not detected in anyone before IP administration).

[0429] Yeast-like fungi of the genus Candida were detected in 7 (46.7%) volunteers before taking the PI and in 3 (20.0%) after taking the PI.

[0430] Other opportunistic bacteria were detected in 6 (40%) volunteers before taking the IP and in 13 (86.7%) after completing the course.

[0431] Seven-day IP administration was shown not to suppress normal intestinal microflora, as no significant deviations from the normal microbiota composition were detected for bifidobacteria, lactobacilli, clostridia, enterococci, typical non-fermenting Escherichia coli, Staphylococcus saprophiticus, and Staphylococcus epidermidis. Elimination of pathogenic lactose-negative Escherichia coli was observed in three volunteers, and elimination of opportunistic Klebsiella pneumoniae was observed in three volunteers. A trend toward identifying certain opportunistic microorganisms was noted: non-hemolytic Staphylococcus aureus was detected in low titers (102 and 103) in 4 volunteers, and other common intestinal flora was detected in 7 volunteers in stool samples after a 7-day course of IP treatment at a dose of 1800 mg per day. The observed changes in microflora composition may reflect temporal variations in the gastrointestinal microbiota, which is subject to significant fluctuations.Further studies on the effect of IP on microflora require repeated studies, involving a larger number of volunteers and with a longer observation period. It should be noted that no increase in Candida infections was detected.

[0432] Thus, it has been shown that the course use of FK5 does not have a significant negative impact on the human microbiota, which is its fundamental advantage over antibiotics.

[0433] Example 10. Study of the pharmacokinetics of a drug based on the developed pharmaceutical composition with a single and course administration in healthy volunteers

[0434] In this study, the tablet form of the pharmaceutical composition FK5 was used.

[0435] The clinical trial design is described in detail in Example 8.

[0436] The pharmacokinetic analysis included data from 23 volunteers (volunteers with sufficient data for analysis): 5 volunteers in group 2 (at a dose of 1800 mg / day), 4 volunteers in group 3 (2400 mg / day), and 14 volunteers in group 4 (a course of treatment at a dose of 1800 mg / day for 7 days). Pharmacokinetics were not assessed in group 1.

[0437] Using validated bioanalytical methods, the concentration of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide and its glucuronide-conjugated metabolite was determined in the whole blood of volunteers (309 samples) and urine of volunteers (108 samples) by HPLC-MS / MS.

[0438] Figures 8 and 7 show the pharmacokinetic profiles of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in healthy volunteers after daily administration of the drug at a dose of 1800 mg or 2400 mg, respectively.

[0439] Tables 15 and 16 present the pharmacokinetic parameters of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in the whole blood of volunteers after daily administration of the study drug at doses of 1800 mg and 2400 mg. Most of the calculated pharmacokinetic parameters exhibit strong variation. Thus, the coefficient of variation (CV,%) for Cmax(1) (the maximum concentration of the first phase) ranges from 57.43% for a dose of 1800 mg to 90.27% for a dose of 2400 mg, for Cmax(2) (the maximum concentration of the second phase) ranges from 58.43% for a dose of 1800 mg to 70.87% for a dose of 2400 mg. The coefficient of variation (CV,%) for Tmax(1) (time to reach the maximum concentration of the first phase) ranges from 34.23% for a dose of 1800 mg to 55.92% for a dose of 2400 mg, for Tmax(2) (time to reach the maximum concentration of the second phase) the coefficient of variation (CV,%) was less variable and changed from 12.45% for a dose of 1800 mg to 22.22% for a dose of 2400 mg.Dose-independent pharmacokinetic parameters—Ke1 (plasma elimination rate constant) and tl / 2 (half-life)—also showed significant variation, with the exception of mean residence time (MRT), where the data were less variable. Thus, the mean residence time (MRT) varied from 17.49% for a dose of 1800 mg to 8.25% for a dose of 2400 mg.

[0440] Analysis of pharmacokinetic parameters showed that the study drug is slowly absorbed into the systemic circulation from the gastrointestinal tract of volunteers. Thus, the Tmax time of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in whole blood changed on average from 3.20±1.10 h (dose 1800 mg) to 2.25±1.26 h (dose 2400 mg) for Cmax(1) and from 17.60±2.19 h (dose 1800 mg) to 18.00±4.00 h (dose 2400 mg) for Cmax(2). The compound under study is absorbed from the gastrointestinal tract after daily administration of various doses of the drug (1800 and 2400 mg) at approximately the same rate (Cmax / AUCO— T (h-1) is a parameter characterizing the rate of absorption of the drug into the systemic circulation). The Cmax / AUCO—>T values ​​were 0.03 - 0.05 h-1.

[0441] To confirm the linearity of the pharmacokinetics of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in whole blood for the parameters Cmax(1), Cmax(2), and AUC0—t, the F-test for linear regression was performed. The significance of the Fisher criterion exceeded 0.05 for all parameters, meaning that these parameters are not linearly dependent on the dose with a 95% probability. It can be said that with a sequential increase in the dose of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide from 1800 to 2400 mg, there is no increase in dose-dependent pharmacokinetic parameters. The half-life (tl / 2) of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide was 27 hours for a dose of 1800 mg and 52 hours for a dose of 2400 mg, which indicates a slow elimination of the drug from the blood.Tables 17 and 18 present the pharmacokinetic parameters of the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in the whole blood of volunteers after daily administration of the study drug at doses of 1800 mg and 2400 mg. As can be seen from these tables, most of the calculated pharmacokinetic parameters exhibited strong variation. Thus, the coefficient of variation (CV,%) for Cmax(1) (maximum concentration of the first phase) ranges from 30.50% for a dose of 1800 mg to 38.31% for a dose of 2400 mg, for Cmax(2) (maximum concentration of the second phase) ranges from 35.28% for a dose of 1800 mg to 29.34% for a dose of 2400 mg.The coefficient of variation (CV, %) for Tmax(1) (time to reach the maximum concentration of the first phase) ranges from 51.60% for a dose of 1800 mg to 40.00% for a dose of 2400 mg, for Tmax(2) (time to reach the maximum concentration of the second phase) the coefficient of variation (CV, %) were less variable and changed from 10.65% for a dose of 1800 mg to 00.00% for a dose of 2400 mg. Dose-independent pharmacokinetic parameters - Ke1 (elimination rate constant from blood plasma), tl / 2 (half-life) - also showed strong variation, with the exception of MRT (mean retention time in the body), where the data were less variable. Thus, (CV,%) MRT changed from 24.80% for a dose of 1800 mg to 19.47% for a dose of 2400 mg. Table 15. Pharmacokinetic parameters of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4b-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in whole blood of volunteers after taking the drug at a dose of 1800 mg.

[0442] > > >

[0443]

[0444] Table 16. Pharmacokinetic parameters of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-Difluorophenyl) arboxamide in the whole blood of volunteers after taking the drug at a dose of 2400 mg.

[0445] > >

[0446]

[0447] 54Table 17. Pharmacokinetic parameters of the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4b-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-arboxamide in the whole blood of volunteers after taking the drug at a dose of 1800 mg.

[0448] > ><

[0449]

[0450] Table 18. Pharmacokinetic parameters of the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl) arboxamide in the blood of volunteers after taking the drug at a dose of 2400 mg.

[0451] > > >

[0452]

[0453] Analysis of pharmacokinetic parameters showed that the study drug is slowly absorbed into the systemic circulation from the gastrointestinal tract of volunteers. Thus, the time to reach Cmax - Tmax of the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in whole blood changed on average from 2.60±1.34 h (dose 1800 mg) to 1.25±0.50 h (dose 2400 mg) for Cmax(1) and from 16.80±1.79 h (dose 1800 mg) to 16.00±0.00 h (dose 2400 mg) for Cmax(2). The compound under study is absorbed from the gastrointestinal tract after daily administration of various doses of the drug (1800 and 2400 mg) at approximately the same rate (Cmax / AUCO—>T (h-1) is a parameter characterizing the rate of absorption of the drug into the systemic circulation). The Cmax / AUCO—>T values ​​were 0.05 - 0.10 h-1.

[0454] To confirm the linearity of the pharmacokinetics of the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in whole blood for the parameters Cmax(1), Cmax(2) and AUC0—>t, the F-test for linear regression was performed. The significance of the Fisher criterion exceeded 0.05 for the parameter Cmax(1), which means that this parameter does not linearly depend on the dose with 95% probability. The significance of the Fisher criterion did not exceed 0.05 for the parameters Cmax(2) and AUC0->t, which means that these parameters are linearly dependent on the dose with 95% probability. For more details, see Section 4.3 of the Pharmacokinetic Report (Appendix 16.1.13.5). Thus, with a consistent increase in the dose of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide from 1800 to 2400 mg, there is no increase in dose-dependent pharmacokinetic parameters for the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide

[0455] The half-life (t1 / 2) of the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide was 26.5 hours for the 1800 mg dose and 35 hours for the 2400 mg dose, indicating slow elimination of the drug from the blood.

[0456] Figures 10 and 11 show the pharmacokinetic profiles of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide and its metabolite in all volunteers (in linear coordinates) for a course of administration of the drug at a dose of 1800 mg. Figures 12 and 13 show a comparative analysis of the average pharmacokinetic profiles of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide and its metabolite after daily and course administration of the drug at a dose of 1800 mg. These data show that the pharmacokinetic profiles of daily and course administration do not match for the first dose taken (first peak), which is most likely due to the incorrect selection of time points for collecting biological samples of whole blood.

[0457] The study showed that the decrease in the concentration of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide and its glucuronide-conjugated metabolite is biphasic, which corresponds to the schedule of daily administration of the drug in doses of 1800 mg (900 mg + 900 mg, 2 times a day at 12-hour intervals) and 2400 mg (1200 mg + 1200 mg, 2 times a day at 12-hour intervals). Regardless of the dose of the administered drug, 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2, 4-difluorophenyl)-carboxamide and its glucuronide-conjugated metabolite are determined in the whole blood of all volunteers (5 volunteers at a dose of 1800 mg and 4 volunteers at a dose of 2400 mg) within 72 hours after daily administration of the drug.

[0458] The study drug is slowly absorbed into the systemic circulation from the gastrointestinal tract of volunteers. Thus, the time to reach the maximum concentration of -Tmax of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in whole blood varied on average from 3.20±1.10 h (dose 1800 mg) to 2.25±1.26 h (dose 2400 mg) for Cmax(1) and from 17.60±2.19 h (dose 1800 mg) to 18.00±4.00 h (dose 2400 mg) for Cmax(2). The studied compound is absorbed from the gastrointestinal tract after daily administration of different doses of the drug (1800 and 2400 mg) at approximately the same rate. The Cmax / AUCO—>t values ​​were 0.03-0.05 h-1. The concentration profiles of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in whole blood, when taking the drug at doses of 1800 mg and 2400 mg, are almost similar, and there is no linearity in the Cmax and AUC0—>t parameters between doses.This result may be due to incorrect timing of whole blood biological sample collection. Analysis of the pharmacokinetic parameters of the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide also showed that the study drug is slowly absorbed into the systemic circulation from the gastrointestinal tract of volunteers. Thus, the Tmax time of the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in whole blood changed on average from 2.60±1.34 h (dose 1800 mg) to 1.25±0.50 h (dose 2400 mg) for Cmax(1) and from 16.80±1.79 h (dose 1800 mg) to 16.00±0.00 h (dose 2400 mg) for Cmax(2). The studied compound is absorbed from the gastrointestinal tract after daily administration of different doses of the drug (1800 and 2400 mg) at approximately the same rate. The Cmax / AUCO—>t values ​​were 0.05 - 0.10 h-1.The concentration profiles of the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in whole blood after administration of the drug at doses of 1800 mg and 2400 mg are almost similar, and there is no linearity of the Cmax and AUC0— t parameters between doses, with the exception of Cmax(2). Thus, it turns out that for the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in the whole blood of volunteers, there is no dose dependence in the first phase, but it is observed in the second phase. The reason for this result may be the incorrect selection of time points for collecting biological samples of whole blood in the first phase.

[0459] Within 36 hours after daily administration of the study drug in doses of 1800 mg and 2400 mg, an average of 0.56x10-3% and 0.96x10-3%, respectively, of unchanged 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide and 0.43% and 0.40%, respectively, of the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide from the administered dose of the drug were detected. Thus, within 1.5 days, 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide and the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide are excreted in extremely small quantities in human urine.

[0460] The concentration profiles of 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in the urine of volunteers, when taking the drug at doses of 1800 and 2400 mg, are dose-dependent, which is also confirmed by the linear nature of the main pharmacokinetic parameters Cmax and AUC 0— > t between doses. The concentration profiles of the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in the urine of volunteers, when taking the drug at doses of 1800 mg and 2400 mg, are almost similar, and there is no linearity of the parameters Cmax and AUC 0— >t between doses.Thus, in contrast to unchanged 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide, the pharmacokinetic profiles of the metabolite 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide in human urine after administration of the drug at doses of 1800 mg and 2400 mg are not dose-dependent. The only explanation for this result is the achievement of saturation of the enzymatic system.

[0461] Thus, the results of the clinical study showed that FC5 has a good, favorable pharmacokinetic profile, which allows it to be used for the prevention of nosocomial infections.

[0462] Example 11. Study of the safety of the drug during a course of treatment in patients on mechanical ventilation and included in clinical trials to study the prophylactic effect of the drug.

[0463] In this study, the tablet form of the pharmaceutical composition FK5 was used.

[0464] A safety study of FK5, 300 mg tablets, for the prevention of nosocomial bacterial infections in patients on mechanical ventilation was conducted as part of a clinical trial (RF Ministry of Health Approval No. 169 dated March 14, 2022) in accordance with the study protocol (06-FT-2021). The study was conducted to obtain preliminary data on the efficacy of FK5 for the prevention of nosocomial bacterial infections, as well as safety data on FK5 in patients on mechanical ventilation.The study included 234 patients in the intensive care unit (ICU) with a diagnosis of severe community-acquired pneumonia, signs of viral lung disease, laboratory-confirmed SARS-CoV-2 infection based on RT-PCR screening, and development of respiratory failure (SpO2 <93%, ARDS, CT scan 3-4) and / or a diagnosis of acute cerebrovascular accident (ACVA) and / or acute heart failure syndrome (AHF), and / or any other medical conditions that necessitated mechanical ventilation. All patients received standard measures to prevent bacterial complications in ICU patients, including those on mechanical ventilation. After connection to mechanical ventilation, the patient could be prescribed a broad-spectrum antibiotic to prevent bacterial infections.

[0465] The total duration of the study could be up to 33 days from the start of screening to the follow-up period and visit, including: screening period (Visit 0, day -2-1) - no more than 48 hours (up to 2 days) from admission to the ICU until the start of taking the study drug (PI) / comparator drug (CD); the period of taking PI / CD up to 17 days, during the patient's stay in the ICU, which can be divided into two stages: stage 1 - the stage before transferring the patient to mechanical ventilation (no more than 3 days) and stage 2 - the stage after transferring to mechanical ventilation (up to 14 days); the visit of the end of taking PI / CD; the follow-up period and visit - on the 14th day after the end of taking PI / CD.

[0466] All patients were randomly assigned to receive FC5 or placebo in a 1:1 ratio, respectively, against the background of standard measures for the prevention of nosocomial infections.

[0467] - patients in group 1 took FK5, 300 mg tablets (Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation) at a dose of 2400 mg / day (4 tablets of 300 mg 2 times a day) during the first 2 days and at a dose of 1800 mg / day (3 tablets of 300 mg 2 times a day) in the following days until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, or the end of the patient's participation in the study for other reasons, but not more than 14 days.

[0468] - patients in group 2 took placebo, 4 tablets 2 times a day during the first 2 days and 3 tablets 2 times a day in the following days until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, or the end of the patient's participation in the study for other reasons, but not more than 14 days.

[0469] As part of the safety study, brief patient case reports were analyzed. These included the study participant's medical history, a description of AEs and SAEs considered significant by the investigator and their outcomes, an assessment of the impact of potential protocol deviations on patient compliance, an assessment of the presence of exclusion criteria, and an assessment of the primary endpoint, as well as an assessment of the SOFA and APACHE II scores. Analysis of the first 47 case reports concluded that the drug had a favorable safety profile and that AEs and SAEs were not associated with the administration of the study drug / placebo in mechanically ventilated patients.

[0470] Studying the safety of the developed composition in patients on mechanical ventilation is an extremely important task, since FK5 is an innovative composition, and an in-depth analysis of its safety in patients on mechanical ventilation is being conducted for the first time.

[0471] As a result of the analysis of case reports, no association was found between the occurrence of adverse events and the use of IP / Placebo in patients connected to ventilators.

[0472] Thus, the results of the clinical study showed that FC5 has good tolerability and a favorable pharmacokinetic profile, which allows it to be used for the prevention of nosocomial infections.

[0473] Example 12. Study of the prophylactic efficacy of a pharmaceutical composition in modeling pneumonia in animals caused by multidrug-resistant (MDR) isolates.

[0474] Ventilator-associated pneumonia (VAP) is a nosocomial pneumonia that can occur in patients connected to ventilators. The incidence of VAP in intensive care units (ICUs) ranges from 9% to 27%, and the mortality rate can reach 20% to 50%.

[0475] The most common pathogens of ventilator-associated pneumonia in the ICU include gram-negative bacteria such as Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii. Despite the expanding knowledge about the causes and agents of ventilator-associated pneumonia and the use of a whole arsenal of methods for its prevention, this lower respiratory tract infection remains a serious complication in patients in the ICU [Guo S. et al. Clinical and molecular characteristics of Klebsiella pneumoniae ventilator-associated pneumonia in mainland China / / BMC Infectious Diseases. - 2016. - V. 16. - P. 1-7., Salehi M. et al. Ventilator-associated pneumonia: multidrug-resistant Acinetobacter vs. extended spectrum beta-lactamase-producing Klebsiella / / The Journal of Infection in Developing Countries. - 2020. - T. 14. - No.

[0476] 06. - C. 660-663.].

[0477] The drug's prophylactic efficacy was studied using a mouse model of pneumonia caused by the most common pathogens of ventilator-associated pneumonia. Isolates of P. aeruginosa, K. pneumoniae, and A. baumannii were isolated in the intensive care unit (ICU) and were characterized by high virulence and multidrug resistance.

[0478] The studies were conducted on inbred DBA / 2 mice, male and female, aged 4-6 weeks, weighing 14-16 grams. Ten animals per group were used, which is sufficient to fully capture the effects being studied. The experiments were repeated twice.

[0479] The bacterial culture was grown in liquid Luria-Bertani medium (LB broth) (DIFCO, USA) at 37°C for 18 hours, centrifuged (6000 rpm, 10 min), the pellet was resuspended in saline and used for infection. To determine the number of CFU (colony forming units), an aliquot of the resulting suspension (100 μl) was taken, a series of serial dilutions were prepared, and 100 μl of the diluted culture was applied to Petri dishes with LB agar. Petri dishes were cultivated at 37°C. After 24 hours of cultivation, the colonies were counted. The concentration of bacteria was expressed as the number of CFU / ml. For infection, the bacterial culture was diluted with saline to the required concentration in accordance with the titer.

[0480] To create experimental pneumonia, mice were anesthetized with inhalation anesthesia. While lightly anesthetized, the animals were intranasally infected with a culture of P. aeruginosa GIMC5O36:PA150608, K. pneumoniae GIMC1006:Kpn-102106, and A. baumannii GIMC5512-ABT-096310. The injected culture volume was 40 µl per mouse.

[0481] The pharmaceutical composition FK4 was administered intragastrically via an atraumatic tube at a dose of 400 mg / kg once daily for 4 days prior to infection. The finished dosage form (tablet) was crushed for this purpose. Placebo was administered according to the FK4 administration schedule. The volume of placebo administered corresponded to the volume of FK administered and was 200 μL. Water from the central water supply was used as a diluent for both FK4 and placebo.

[0482] To detect P. aeruginosa, K. pneumoniae, and A. baumannii in the lungs, organ samples were homogenized in 1 ml of saline, and the resulting homogenates were centrifuged for 10 min at 800 rpm (0.8 ref) to remove coarse tissue debris. Ten-fold dilutions were prepared from the initial homogenate suspension in saline. One hundred microliters of each dilution were placed on LB agar-coated Petri dishes and incubated at 37°C. After 24 hours of cultivation, the grown colonies were counted. The concentration of P. aeruginosa, K. pneumoniae, and A. baumannii in the lungs was expressed as the number of CFU per organ. The bacterial load in the lungs of mice was studied on the second day after infection.

[0483] The aim of this stage of the work was to study the prophylactic efficacy of FC4 against model pneumonia in animals caused by isolates of P. aeruginosa, K. pneumoniae and A. baumannii with multidrug resistance (MDR).

[0484] Study of the prophylactic efficacy of FC4 against a model of pneumonia in animals caused by the isolate P. aeruginosa GIMC5O36:PA150608

[0485] P. aeruginosa is one of the most common pathogens in ventilator-associated pneumonia, and its detection is often associated with high mortality and prolonged treatment duration. In a model of pneumonia caused by the P. aeruginosa isolate GIMC5036:PAl 50608, mice were infected intranasally at a dose of 5x10 6 CFU / mouse. FC4 was administered prophylactically for 4 days prior to infection of mice at a dose of 400 mg / kg once daily. The experimental results are presented in Table 17.

[0486] It was shown that in the control group, when P. aeruginosa GIMC5O36:PA150608 was administered at a dose of 5x10 6CFU / mouse, a 70% mortality rate was observed. When FK4 was administered prophylactically, the survival rate was 100%. Meanwhile, in the control group, surviving mice experienced significant weight loss during the first three days after infection, were unfed, sedentary, and had labored breathing. The condition of the surviving animals stabilized only by the fifth day. When FK4 was administered, the condition was painful only on the first day and had practically recovered by the second day after infection.

[0487] Table 17. Results of the study of the effectiveness of prophylactic use of FC4 in modeling pneumonia caused by the MDR isolate of P aeruginosa GIMC5O36:PA150608

[0488]

[0489] When studying the bacterial load in the lungs on the 2nd day after infection, it was shown that prophylactic use of FC4 reduced the number of bacteria in the lungs by several orders of magnitude, which correlated with an improvement in the general condition of the mice.

[0490] Thus, it was shown that oral administration of FC4 for 4 days prior to infection of animals in a model of pneumonia caused by P. aeruginosa increases the survival of mice and reduces the bacterial load in the lungs.

[0491] Study of the prophylactic efficacy of FC4 against a model of pneumonia in animals caused by the isolate K. pneumoniae GIMC1006:Kpn-102106

[0492] K. pneumoniae is a common pathogen found in both hospital-acquired and community-acquired pneumonias. K. pneumoniae also causes various infections, such as meningitis, septicemia, and purulent abscesses. In a model of pneumonia caused by the K. pneumoniae isolate GIMC1006:K.pn-102106, mice were infected intranasally at a dose of 10 7 CFU / mouse. FC4 was administered prophylactically for 4 days prior to infection of mice at a dose of 400 mg / kg once daily. The experimental results are presented in Table 18.

[0493] In the control group, with intranasal administration of K. pneumoniae GIMC1006:Kpn-102106 at a dose of 10 7 CFU / mouse, a 70% mortality rate was observed. Prophylactic administration of FK4 at a dose of 400 mg / kg per day increased the survival rate of mice to 90%. Observation of animals showed that in the control group, in the first 3 days after infection, the condition of the mice gradually worsened and symptoms of respiratory failure increased. The animals ate little and lost weight. Death began on the third day after infection. Moreover, with the prophylactic use of FK4, the condition of most mice did not worsen, appetite was restored on days 2-3 after infection, and no symptoms of respiratory failure were observed. Table 18. Results of a study of the effectiveness of prophylactic use of FK4 in modeling pneumonia caused by the MDR isolate K. pneumoniae GIMC1006:Kpn-102106

[0494]

[0495] Along with increased survival in mice, a decrease in the bacterial load in the lungs was also noted on day 3 post-infection. In the control group, accumulation of K. pneumoniae GIMC1006:Kpn-102106 was detected, with bacteria detected in some cases in quantities exceeding the infection dose. Furthermore, prophylactic administration of FK4 led to a significant reduction in the bacterial load in the lungs, which also correlated with increased survival and improved overall condition of the mice.

[0496] Thus, for the MDR isolate K. pneumoniae GIMC1006:Kpn-102106, the effectiveness of prophylactic use of FK4 was also demonstrated in modeling pneumonia.

[0497] Study of the prophylactic efficacy of FC4 against a model of pneumonia in animals caused by the A. baumannii isolate GIMC5512-ABT-096310

[0498] A. baumannii is one of the most common pathogens of ventilator-associated pneumonia and, due to the rapid development of resistance to most antimicrobials, is associated with an extremely high mortality rate. In a model of pneumonia caused by the A. baumannii isolate GIMC5512-ABT-096310, mice were infected intranasally at a dose of 5.10 8 CFU / mouse. The drug was administered prophylactically for 4 days before infecting mice at a dose of 400 mg / kg once a day.

[0499] Mice were infected intranasally with an infectious dose of A. baumannii GIMC5512-ABT-096310 5x10 8 CFU / mouse, which resulted in the development of lung colonization by A. baumannii, but no animal mortality was observed. The experimental results are presented in Table 19.

[0500] It was shown that after intranasal infection, the condition of the mice in the control group gradually worsened over the first two days: they showed no interest in food, weight loss, and signs of respiratory failure. In the group of mice prophylactically treated with FK4, motor activity was reduced to a lesser degree, weight loss was not observed, and there were no signs of respiratory failure.

[0501] A study of lung colonization two days after infection revealed that in the control group, despite deteriorating general health and the development of signs of respiratory failure, A. baumannii GIMC5512-ABT-096310 was detected in the lungs at high titers. Prophylactic administration of FK4 resulted in a significant reduction in the bacterial load in the lungs, which, as in previous experiments, correlated with the overall health of the mice.

[0502] Table 19. Results of the study of the effectiveness of prophylactic use of the pharmaceutical composition in modeling pneumonia caused by the MDR isolate A. baumannii GIMC5512-ABT-096310

[0503]

[0504] The results of the study demonstrated the effectiveness of the prophylactic use of FK4 in modeling pneumonia in mice caused by the isolate A. baumannii GIMC5512-ABT-096310, which has multiple drug resistance. Thus, in a model of pneumonia in mice caused by clinical multidrug-resistant isolates of P. aeruginosa GIMC5O36:PA150608, K. pneumoniae GIMC1006:Kpn-102106 and A. baumannii GIMC5512-ABT-096310, it was experimentally shown that the use of the developed pharmaceutical composition in a prophylactic mode for 4 days before infection led to an increase in the survival rate of mice, a significant decrease in the bacterial load in the lungs and an improvement in the general condition of the animals.

[0505] The given examples confirm the possibility of using a pharmaceutical composition containing 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide for the prevention of nosocomial infections.

[0506] Example 13. Study of the development of pathogen resistance to a drug based on the developed pharmaceutical substance in vivo.

[0507] The aim of this study was to determine the effect of a medicinal product based on the developed pharmaceutical substance FK5 on the long-passaged strain P. aeuginosa 1840-21 in comparison with the strain P. aeuginosa 1840 in a pneumonia model in mice.

[0508] To determine the virulence and sensitivity of strain 1840 after 21 passages to FK5 in in vivo experiments, an acute pneumonia model in mice was used. For comparison, an acute pneumonia model with strain 1840 infection was used. Four groups were formed. In groups 1 and 2, mice were infected with strain 1840-21 P. aeuginosa at a dose of 3.5 x 10 6 CFU / mouse. For groups 3 and 4, strain 1840 was used at a dose of 3.2 x 10 6 CFU / mouse. Mice were infected intranasally. Therapy for the treatment group was carried out according to the following regimen: FC5 was administered to animals at a dose of 50 mg / kg (1 mg / mouse) twice a day. Treatment of the animals began simultaneously with infection and continued for 4 days. To assess the mortality dynamics, mice were infected with an LD50 dose. The experimental results are presented in Table 20. Table 20 - Results of monitoring the mortality dynamics of mice infected with clinical isolates 1840-21 and 1840 and treated with FC5

[0509]

[0510] * differences with the control group are significant: p<0.05.

[0511] In the control groups (Groups 1 and 3), the mortality rate of mice was 50% in each group. In the FC5 treatment groups (Groups 2 and 4), when challenged with the same dose, the survival rate of animals was 100%. The average lifespan in control groups 1 and 3 was 77.5% and 70%, respectively. In treatment groups 2 and 4, the lifespan of animals was the same, at 100%.

[0512] Thus, it was demonstrated that strain 1840-21 causes acute pneumonia comparable to that caused by strain 1840, and long-term passaging of strain 1840-21 does not result in a loss or reduction of virulence. In a model of acute pneumonia caused by strain 1840-21, it was shown that treatment with FK5 at a dose of 50 mg / kg (1 mg / mouse) twice daily blocks the development of acute infection and provides 100% protection against mortality when challenged with the LD50 dose. The results of treatment of pneumonia caused by the long-passaged strain are comparable to those of pneumonia caused by strain 1840.These experiments showed that the long-passaged strain 1840-21 remains sensitive to FK5, treatment with which has a 100% protective effect when animals are infected with an LD50 dose, which indicates the absence of the formation of resistance to the T3SS inhibitor under conditions of long-term exposure to pseudomonads, in contrast to the rapidly developing resistance to antibiotics during the selection of resistant variants.

[0513] Example 14. Monitoring antibiotic resistance of clinical isolates of multidrug-resistant gram-negative bacteria isolated from intensive care units and assessing their sensitivity to FC5.

[0514] Within the framework of the Agreement on scientific cooperation between the Kommunarka Moscow Medical and Clinical Center of the Ministry of Health of the Russian Federation and the Gamaleya National Research Center for Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, a number of clinical isolates of microorganisms were transferred (Table 21).

[0515] Table 21. List of isolates of microorganisms transferred to the Kommunarka Medical and Clinical Center of the Moscow Health Department

[0516] ""

[0517]

[0518] K. pneumoniae ST395 belongs to the international "high-risk" clone: ​​CG395,

[0519] The frequency of occurrence of which in Russia was 45.6% in 2020. The Pasteur MLST database contains 163 isolates from Russia belonging to ST395. Isolates isolated from the same patient did not differ in genomic characteristics. Both were characterized

[0520] hypermucoidism and the presence of gene clusters responsible for iron absorption: the aerobactin cluster and yersiniabactin. Genomic characteristics confirmed multidrug resistance of the isolates (Table 22).

[0521] Table 22. Resistance predicted by CARD (The Comprehensive Antibiotic Resistance Database) analysis

[0522]

[0523] The analysis included two isolates of B. baumannii, isolated from different patients in ICU 10. They belonged to different genotypes in the context of MLST genes. Genotype 231 was previously noted in Smolensk from 2006 to 2018 (according to the PubMLST database). Genotype 1816 / 195 was identified.

[0524] for the first time, but belongs to the international high-risk clone CC92 / CC2, the frequency of which in Russia was 60.3% in 2020. Isolates ST1816 / 195, according to the PubMLST database, have been registered in China, Lebanon, South Africa and Iraq.

[0525] Multiple antibiotic resistance was confirmed by genomic characteristics (Table 23).

[0526] Table 23. Resistance to beta-lactamases

[0527]

[0528]

[0529] One P. aeruginosa isolate, isolated from a locus more characteristic of carriage and community-acquired P. aeruginosa, was submitted for analysis. Its MLST genotype is 277, registered 80 times in the PubMLST database for Russian isolates. Analysis of resistance loci revealed a large number of efflux system genes, as well as loci responsible for enzymatic activity or its regulation. This isolate can also be considered multidrug-resistant.

[0530] For the pathogens studied, models were selected that were most representative of the diseases they cause: acute pneumonia and generalized infection. In the first stage, infection doses that resulted in lethal infection were determined.

[0531] The effectiveness of FC5 was assessed by two standard parameters for antibacterial drugs: animal survival and eradication of the pathogen from organs.

[0532] The obtained results showed that for all three analyzed resistant isolates, a significant decrease in animal mortality and an increase in lifespan were observed. For pseudomonads at LD100, mortality decreased to 10%, for Klebsiella - to 46.6%, for Acinetobacter - to 60%. At the same time, the lifespan of mice increased by 2 times (see 2.6.2.2.22 for GIMC5O36:PA150608 P. aeruginosa, - 2.6.2.2.2.27.3 for K. pneumoniae GIMC1006:Kpn-102106; 2.6.2.2.2.29.3 for A. baumannii GIMC5512-ABT-096310).

[0533] An evaluation of the pathogen eradication efficacy in animal organs revealed a significant reduction in bacterial load under the drug's action. In lung tissue and blood of mice infected with all isolates, a 3-4-order-of-magnitude reduction in the median number of isolated pathogens was observed as early as the second day compared to the control. Moreover, bacteria were completely absent in some animals. Thus, a study of the efficacy of FK5 in models of acute mouse infections caused by multidrug-resistant isolates of Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae isolated from the Intensive Care Unit of the Kommunarka Medical Clinical Center of the Moscow Health Department demonstrated the drug's antibacterial activity, previously demonstrated with isolates obtained from other hospitals.

[0534] The obtained results demonstrate the antibacterial activity of FK5 against multidrug-resistant bacteria, including those at the critical priority level: carbapenem-resistant Pseudomonas, Acinetobacter, and Enterobacteriaceae. These pathogens are the most challenging to treat in life-threatening hospital-acquired infections.

[0535] Example 15 Study of the suppression of flagellum-associated motility of P. aeruginosa under the action of the developed pharmaceutical substance.

[0536] The flagellum is a bacterial surface structure that enables bacterial motility in liquid and semi-liquid environments, adherence to cells, dissemination of bacteria throughout the body, and initiation of inflammatory responses. The flagellum is a significant virulence factor, as its functions are essential for the development of the infectious process at various stages of the disease. The type III secretion system and the flagellum are closely related phylogenetically and share a similar structure of the basal body and cytoplasmic region. The low-molecular compound FK5 exhibits inhibitory activity against both the type III secretion system and the flagellum. The most demonstrative test for assessing flagellum activity in vitro is the method for determining bacterial motility in semi-liquid agar during laboratory cultivation.

[0537] To study the biological activity of the obtained pharmaceutical composition, a test was performed to evaluate the inhibition of the motility of the isolate Pseudomonas aeruginosa CL-2943. To assess the motility of bacteria, the culture was grown overnight at 37°C with aeration on a shaker (200 rpm), normalized according to ODeoo and diluted 100-fold with Luria-Bertani (LB) broth (Difco-Becton). Bacterial suspensions were incubated for 3 h at 37°C with aeration on a shaker (200 rpm) until the logarithmic growth phase, then inoculated into the center of 0.3% agar (with the addition of 1% tryptone and 0.5% sodium chloride) and incubated for 24 h at 37°C. Bacterial motility was assessed by the diameter ( = mm) of the bacterial migration zone from the center of the dish. These values ​​served as positive controls when assessing the effect of the inhibitor on bacterial motility.

[0538] A suspension of the pharmaceutical composition FK1 was prepared with a final concentration of 5 mM. The suspension was then added at a dose of 100 μg / ml to a 0.25% semi-solid agar medium cooled to 45-50°C and poured into Petri dishes. The activity of the substances was assessed based on the diameter (4 = mm) of the bacterial movement zone, compared to control samples.

[0539] The experimental results are presented in Fig. 14. It is clearly evident that the addition of the pharmaceutical composition FK1 to the growth medium almost completely inhibits the motility of Pseudomonas aeruginosa. Measurement of the bacterial motility zone revealed significant inhibition of motility.

[0540] Thus, the conducted study showed that the developed composition FK1 has inhibitory activity specific to flagellar motility.

[0541] Example 15 Suppression of B. cenocepacia infection in a long-term colonization pulmonary infection model

[0542] To develop the model, the B. cenocepacia isolate GIMC4612:Bcn34P14, isolated from the sputum of a patient with cystic fibrosis, was used.

[0543] The effect of FK5 was assessed based on its impact on bacterial load, animal survival, and the histological picture of lung condition. The effect of FK5 on lung colonization in a model of experimental pulmonary infection caused by the B. cenocepacia isolate GIMC4612:Bcn34P14 was assessed on days 2, 5, 7, and 10 postinfection. Microbiological examination of lung homogenates on day 2 postinfection revealed no significant difference between the control and experimental groups. On day 5 postinfection, FK5 reduced the B. cenocepacia load in the lungs by several orders of magnitude compared to the control group, and this trend persisted on day 7. On day 10 postinfection, either a significant decrease in the number of B. cenocepacia in the lungs of mice receiving FK5 or, in most cases, complete eradication of the pathogen was observed. In the control group, on the 10th day after infection, the bacterial load remained within 10 3 CFU / ml (Fig. 15).

[0544] During the first two days of observation, infected animals in both groups exhibited a moderate loss of appetite, moderate to mild dehydration, and decreased activity. However, most animals in the FC5 prevention / treatment group stabilized by days 2 and 3 of observation, with activity and appetite returning to normal. No deaths were observed in the treatment group throughout the entire observation period. In the control group of mice infected with B. cenocepacia without FC5 treatment, signs of infection were more pronounced and, beginning on day 3 of observation, were characterized by a deterioration in the animals' condition, including ruffled fur, loss of appetite, increasing apathy, and labored breathing, ultimately leading to death.This experiment demonstrated that a regimen including prophylactic administration and subsequent treatment with FK5 increased the survival rate to 100% compared to the control group, where the survival rate was 50%. Surviving animals in both groups were observed for up to 10 days after infection; no further deaths were observed. These data demonstrate the effectiveness of the chosen dosage and regimen of FK5 in an experimental model of pulmonary infection with long-term colonization caused by B. cenocepacia (Fig. 16).

[0545] Histological examination of lung tissue samples from the control group revealed the following changes: protein exudate in the airways, macrophage proliferation, diffuse hemorrhage into the alveolar space, and bronchiolar obstruction by masses consisting of macrophages, leukocytes, and postcellular protein structures. Desquamation of the bronchiolar epithelium, parenchymal compaction due to leukocyte infiltration mixed with hemorrhage, and foci of necrosis were observed. This pattern is consistent with extensive lobar pneumonia.

[0546] Histological examination of lung tissue samples from the group receiving FC5 prophylaxis and treatment revealed marked vascular congestion throughout the vasculature and an absence of intraalveolar edema. Lobar pneumonia alternated with focal pneumonia, or several small foci of inflammation were present along the bronchi. These foci of inflammation were more common in perivascular spaces and appeared as more organized areas (compared to previous samples from the control group), visually demarcated from the surrounding healthy tissue, and composed predominantly of neutrophils and macrophages. Protein masses and macrophages were detected within the bronchiolar lumen. The pattern was consistent with focal pneumonia.

[0547] Thus, the antibacterial efficacy of the developed pharmaceutical composition was demonstrated in a model of lung infection with long-term colonization caused by B. cenocepacia.

[0548] Example 16. Study of the antibacterial efficacy of FC5 in comparison with antibiotics of different classes (Meropenem, Jamsul, Ciprofloxacin) in a model of acute pneumonia caused by P.aeruginosa.

[0549] The aim of the study was to investigate the antibacterial efficacy of the developed pharmaceutical composition FK5 in a model of acute pneumonia caused by P.aeruginosa in monotherapy or in combination with antibiotics of various classes.

[0550] Dosage and administration regimen: 1) FC5, prophylaxis 4 days, treatment 5 days, 250 mg / kg (active ingredient) orally once a day.

[0551] 2) Meropenem, treatment for 5 days, 128 mg / kg (active substance) intraperitoneally 2 times a day.

[0552] 3) Jamsul, treatment for 5 days, 168 mg / kg (active substance) intraperitoneally 2 times a day.

[0553] 4) Ciprofloxacin, treatment for 5 days, 42 mg / kg (active ingredient) orally 2 times a day.

[0554] For infection, a clinical isolate of Pseudomonas aeruginosa GIMC5036: PAI 50608 with exoS was used. + genotype. Table 24 shows the data on the sensitivity of this isolate to antibiotics, obtained using the disk diffusion method.

[0555] Table 24 - Sensitivity of Pseudomonas aeruginosa isolate GIMC5O36:PA150608

[0556]

[0557]

[0558] Animals: 4-5-week-old male or female DBA / 2 mice weighing 16-18 grams, 72 animals. The animals were maintained under standard conditions in the vivarium of the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Ministry of Health in accordance with Sanitary Regulations and Standards 3.3686-21 "Sanitary and Epidemiological Requirements for the Prevention of Infectious Diseases." The mice were evenly distributed among three experiments, each consisting of four groups of six mice, and each experiment was performed in duplicate.

[0559] To evaluate the efficacy of FC5 in comparison with Meropenem in a model of acute pneumonia caused by P. aeruginosa infection, the following groups of animals were formed:

[0560] 1) Infection 5xU 6 CFU / mouse P aeruginosa (control group)

[0561] 2) Infection 5xU 6 CFU / mouse P aeruginosa. Prevention and treatment of FC5

[0562] 3) Infection 5xU 6 CFU / mouse P aeruginosa. Prevention and treatment with FC5, treatment with Meropenem

[0563] 4) Infection 5xU 6 CFU / mouse P. aeruginosa. Treatment with Meropenem

[0564] The results of the experiment are presented in Table 24 and Fig. 17.

[0565] Table 1. Average lifespan of mice infected with P. aeruginosa GIMC5036.PA150608 and treated with FK5 and / or the antibiotic Meropenem (data are summarized from two experiments)

[0566]

[0567]

[0568] In the control groups, the condition of the mice after infection was severe, with difficulty breathing and apathy, anorexia in most individuals developing in the first day after infection and persisting until death; all mice died within 4 days after infection.

[0569] In the group of mice treated only with meropenem, the condition of most animals in both experiments was severe or moderate, consistent with the isolate's resistance to this antibiotic. The mice were apathetic, exhibited anorexia, and most had diarrhea. Appetite was restored in surviving mice on the third day of therapy. Mortality occurred in 5 of 12 mice on the second and third days after infection.

[0570] In the group receiving combined prophylaxis and treatment with FK5 and meropenem, the mice showed satisfactory condition. On the first day after infection, some mice exhibited pronounced apathy and anorexia, with rapid breathing. Appetite was restored, and their condition stabilized on the second day of combination therapy. However, throughout the entire observation period, most mice experienced diarrhea and ruffled fur. In the first experiment, all mice survived; in the second experiment, one mouse died on the third day after infection.

[0571] In the FC5 prophylaxis and treatment group, apathy and anorexia were observed in all mice only on the first day and in some mice on the second day after infection; their condition then stabilized. A significant difference from the combination therapy group was the absence of diarrhea in mice in this group. Mice demonstrated better appetite and activity compared to mice in the other groups. One mouse died in the second experiment, on the fourth day after infection.

[0572] To evaluate the effectiveness of FK5 in comparison with Jamsul in the model of acute pneumonia caused by P. aeruginosa infection, the following groups of animals were formed:

[0573] 1) Infection 5x10 6 CFU / mouse P aeruginosa (control group)

[0574] 2) Infection 5x10 6 CFU / mouse P aeruginosa. Prevention and treatment of FC5

[0575] 3) Infection 5x10 6 CFU / mouse P aeruginosa. Prevention and treatment of FC5, treatment with Jamsul

[0576] 4) Infection 5x10 6 CFU / mouse P. aeruginosa. Treatment with Jamsul

[0577] The results of the experiment are presented in Table 25 and Fig. 18.

[0578] Table 2. Average lifespan of mice infected with P. aeruginosa GIMC5O36:PA150608 and treated with FK5 and / or the antibiotic Jamsul (data summarized for two experiments)

[0579]

[0580] In the control groups, the mice showed severe post-infection symptoms, including labored breathing, apathy, and anorexia. Most mice developed anorexia within the first 24 hours after infection and persisted until death. All mice died within 4 days after infection. In the group of mice treated only with Jamsul, the animals' condition was severe in both experiments, beginning on the first day after infection, consistent with data indicating the isolate's resistance to this antibiotic. During the observation period, mice exhibited decreased appetite or anorexia, decreased activity, and symptoms of dehydration (ruffled fur, enophthalmos). Seven out of 12 mice died in both experiments.

[0581] In the group receiving combined prophylaxis and treatment with FK5 and Jamsul, some mice exhibited apathy and anorexia, rapid breathing, and increased respiratory rate until the second day after infection. Appetite was restored, and their condition stabilized by the second or third day of combination therapy. In the first experiment, one mouse died on the second day; in the second, one mouse died on the fourth day after infection.

[0582] In the group receiving FC5 prophylaxis and therapy, apathy, anorexia, and decreased activity were observed in mice only on the first day after infection, then on the second and third days, their condition stabilized. There were no deaths in the first experiment. In the second experiment, mortality was recorded: one mouse died on the fourth day after infection.

[0583] To evaluate the effectiveness of FC5 in comparison with Ciprofloxacin in the model of acute pneumonia caused by P. aeruginosa infection, the following groups of animals were formed:

[0584] 1) Infection 5x10 6CFU / mouse P aeruginosa (control group)

[0585] 2) Infection 5x10 6 CFU / mouse P aeruginosa. Prevention and treatment of FC5

[0586] 3) Infection 5xU 6 CFU / mouse P. aeruginosa. Prevention and treatment with FC5, treatment with Ciprofloxacin

[0587] 4) Infection 5x10 6 CFU / mouse P. aeruginosa. Treatment with Ciprofloxacin The results of the experiment are presented in Table 26 and Fig. 19. Table 3 - Average lifespan of mice infected with P. aeruginosa GIMC5O36:PA150608 and treated with FK5 and / or the antibiotic Ciprofloxacin (summarized data from two experiments)

[0588]

[0589] In the control groups, the condition of the mice after infection was severe, with difficulty breathing and apathy. Anorexia developed in most individuals within the first day after infection and persisted until death; all mice died within 4 days after infection.

[0590] In the group of mice treated only with ciprofloxacin, the condition of the mice varied from severe to poor during the first three days, consistent with data indicating the isolate's resistance to this antibiotic. Apathy, decreased appetite, and signs of dehydration (enophthalmos, ruffled fur) were observed, and diarrhea was observed in several mice. In two experiments, 7 out of 12 mice died between the second and fourth days after infection.

[0591] In the group receiving combined prophylaxis and treatment with FK5 and ciprofloxacin, the mice's condition was satisfactory. Until the third day after infection, some mice showed decreased activity and appetite, slight fur ruffling, and a few developed diarrhea. Appetite was restored and their condition stabilized by the third day of combination therapy. In the first experiment, one mouse died on the second day; in the second, one mouse died on the third day.

[0592] In the FC5 prophylaxis and treatment group, a worsening of the condition, manifested by decreased activity and appetite, was observed in all mice only on the first day and in some mice on the second day after infection; the condition then stabilized. No diarrhea was observed. The mice demonstrated better appetite and activity compared to mice in the other groups. One mouse died in the second experiment, on the fourth day after infection.

[0593] Thus, the results of the experiments showed that monotherapy with antibiotics, meropenem, jamsul, and ciprofloxacin, was not highly effective, which is associated with the pathogen's resistance to the antibiotics used. Survival across all antibiotic treatment groups did not exceed 50% in a pneumonia model with 100% mortality.

[0594] Treatment with FC5 using a proven, effective regimen, including prophylaxis and therapy, demonstrated high efficacy, with a nearly 100% survival rate in mice. Concomitant use of FC5 and antibiotics increased the effectiveness of treatment with Meropenem (91.7% survival), Ciprofloxacin (83.3% survival), and Jamsul (83.3% survival).

[0595] Thus, the developed pharmaceutical composition can be used both as monotherapy and in combination with known antibiotics. The given examples confirm the possibility of using a pharmaceutical composition containing 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide for the prevention of nosocomial infections.

[0596] Example 17 Effect of FC5 on the internalization and intracellular replication of Klebsiella pneumoniae in A-549 epithelial cells.

[0597] The potential for chronic infections and the ineffectiveness of antibacterial therapy are largely linked to the intracellular persistence of pathogens. Both intracellular pathogens and extracellular bacteria have developed the ability to form intracellular reservoirs, so-called intracellular communities, which are inaccessible to many antibiotics and immune defense factors. This persistence of pathogens determines the recurrent nature of infections.

[0598] FK5's pharmacological properties are characterized by high penetration through lipid membranes, accumulation in tissues and within cells, and maintaining cellular activity. Therefore, a study was conducted on the effects of FK5 on intracellular bacterial proliferation.

[0599] Bacterial internalization in A-549 cells (human lung carcinoma) was assessed after 1 hour and 4 hours. For this purpose, the cells were cultured in a 24-well plate overnight before infection with the bacterial culture. To assess the effect of FK5 (20 μg / ml) on the ability of isolates to penetrate and survive inside A-549 cells, the drug was added to the medium simultaneously with the bacteria, and the plate was incubated for 1 hour at 37°C. After removal of the supernatant, gentamicin was added (the gentamicin concentration was determined by the MIC) and the plate was incubated for 1 hour to remove extracellular bacteria. The plates were then washed and, for microscopic analysis, the slides were fixed with acetone and stained with mouse antibodies for 30 min and anti-mouse IgG-FITC conjugate (Merck, New Jersey, USA) for 30 min at 37°C and 5% CO2. Bacterial internalization into cells was assessed under a fluorescence microscope (Nikon Eclipse 50i, Nikon, Japan) with a 100x objective with oil immersion.For quantitative characterization, cells infected with bacterial cultures were lysed with 0.25% Triton X-100 (Sigma) for 10 min at room temperature. Uninfected cells served as a negative control. The culture lysates were then plated on LB-arap using serial dilutions. The number of intracellular bacteria was expressed as colony-forming units (CFU) by counting bacterial colonies. Values ​​were calculated as the average value from the bacterial population of two wells in triplicate experiments. Bacterial internalization after 4 h was performed in a similar manner.

[0600] To assess the effect of FK5 on bacterial internalization after 1 and 4 h, the drug was added to each well simultaneously with cell infection at a final concentration of 20 μg / ml. Intracellular survival of bacteria in A-549 cells was assessed 24 h after infection with bacterial cultures, as described previously (section 1.5). After 4 h, gentamicin was added to exclude adherent bacteria from those invaded 24 h after infection. To assess the effect of FK5 on the ability of bacteria to survive inside cells, the drug was added simultaneously with infection at a final concentration of 20 μg / ml. Quantification and microscopic studies were performed as described previously. Values ​​were calculated as the average of the bacterial populations from two wells in triplicate experiments.

[0601] The results are presented in Table 27.

[0602] Table 27. Seeding results.

[0603]

[0604] FC5 affects the ability of the clinical isolate K. pneumoniae GIMC1042:Kpn34P66 to internalize and replicate in A-549 cells

[0605] Incubation of K. pneumoniae with A-549 cells for 1 hour resulted in the formation of intracellular bacteria in the amount of 1.0<10 4 (6x10 3) КОЕ / ml. When FK5 was introduced simultaneously with cell infection, the number of intracellular bacteria was 2.0x10 3 (4x10 3 ) CFU / ml. Thus, no significant difference was observed between the groups.

[0606] FC5 does not reduce the internalization of K. pneumoniae GIMC1042:Kpn34P66 bacteria 1 hour after infection of A-549 cells. Data were assessed by the number of internalized bacteria using lysate culture on LB arap. Data represent values ​​from two independent experiments.

[0607] After 4 hours of internalization of K. pneumoniae bacteria in A-549 cells, an increase in the bacterial load was observed, which amounted to 3.6><106 (1.2x10 6 ) CFU / ml. The addition of FC5 had no effect on reducing the number of intracellular bacteria in cells 1.3x10 6 (9x10 5 ) CFU / ml)

[0608] FC5 does not reduce the internalization of K. pneumoniae GIMC1042:Kpn34P66 bacteria 4 hours after infection of A-549 cells. The data were assessed by the number of internalized bacteria using lysate culture on LB arap. The data represent values ​​from two independent experiments.

[0609] After 24 hours, a decrease in the bacterial load in A-549 cells to the 5th degree of 1.4X10 is observed. 5 (2x10 5 ) CFU / ML). At the same time, prolonged incubation with FK5 for 24 hours allows to reduce bacterial replication in A-549 cells to 5x10(7x10 1 )CFU / ml.

[0610] FC5 reduces the replication of K. pneumoniae GIMC1042:Kpn34P66 bacteria within a-549 cells after 24 hours. The data were assessed by bacterial counts using lysate culture on LB arap. The data represent the values ​​from two independent experiments.

[0611] Example 18. Suppression of S. aureus biofilm formation under the influence of the developed pharmaceutical composition.

[0612] In this study, we used the developed pharmaceutical composition FK5. To evaluate the effect of FK5 on the ability of bacteria to form biofilms, clinical isolates from patients with urinary tract infections, resistant to various antibacterial drugs, and a sensitive museum strain were selected on 96-well polystyrene plates. A solution of FK5 in acetate buffer was added to the nutrient medium at final concentrations of 60 and 100 μg / ml. S. aureus biofilms were cultured at 37°C for 48 hours with daily medium replacement. Upon completion of cultivation, the resulting biofilms were stained with crystal violet, and the bound dye was extracted with ethanol. The results are presented graphically (Fig. 20).

[0613] The presence of FC5 during biofilm formation results in a dose-dependent reduction in biofilm density. FC5 at a concentration of 100 μg / ml reduces the biofilm-forming capacity of S. aureus by 34.50–80.02%, with the greatest reduction observed for clinical isolate No. 25008.

[0614] To assess the effect of the FK5 preparation on the ability of bacteria to form biofilms on glass, sterile glass was placed in the wells of a 24-well plate, and S. aureus was cultivated for 48 hours with the addition of the FK5 preparation at final concentrations of 60 and 100 μg / ml.

[0615] To visualize the S. aureus biofilm, it was stained with crystal violet and examined under a microscope. Thirty fields of view were examined, and the most representative images were selected for display. All strains showed a significant reduction in biofilm density compared to the control when the drug was added at concentrations of 60 μg / ml and 100 μg / ml. Micrographs show that FK5 dose-dependently reduces the density of S. aureus biofilms for both antibiotic-sensitive control strains and clinical isolates with varying degrees of resistance.

[0616] To study the dynamics of biofilm formation and the effect of the drug on this process, the strain showing the greatest reduction in biofilm density under the influence of FC5 was selected for each species. The S' aureus 25008 biofilm was cultured for 24 and 48 hours. Since spontaneous biofilm destruction was observed at later times, the most effective concentration of FC5—100 μg / ml—was used in the experiment.

[0617] Micrographs (Figs. 21–23) demonstrate that FC5 inhibits biofilm formation at all stages of S' aureus cultivation. This indicates that FC5 influences both the initial stages of biofilm formation, namely bacterial adhesion to the abiotic surface, and interbacterial interactions at later stages of biofilm formation. It prevents the formation of intensive biofilm even after 48 hours of cultivation and results in the formation of only single-layer macrocolonies. Without the addition of the preparation, the studied pathogens form mature multilayer biofilms at these stages.

[0618] Scanning electron microscopy was used to study the ultrastructural organization of biofilms. Based on previous experiments, a culture period was selected that demonstrated the formation of the most dense biofilm.

[0619] Data obtained using scanning electron microscopy and light microscopy demonstrated that FK5 effectively inhibits S. aureus biofilm formation regardless of the isolate's resistance to antibacterial agents. Mature biofilm formed only in control samples; when exposed to FK5, the biofilm did not form a multilayer structure, and only scattered bacterial clusters were observed. These results demonstrate the efficacy of FK5 in inhibiting S. aureus biofilm formation on various abiotic surfaces and the dose-dependent nature of this effect.

[0620] Example 19 Inhibition of E. coli biofilm formation

[0621] To study the formation process in detail, both biofilm formation and exopolysaccharide production were assessed in E. coli isolates.

[0622] The E. coli isolate GIMC1402:EC-33P15 grew slowly due to its mucoid nature, so biofilm formation was assessed dynamically after 24 h, 48 h, and 72 h. After 24 h, dense bacterial connections began to form along the well ring (Fig. 24). After 48 h and 72 h, denser bacterial clusters formed and biofilm biomass increased: 2-fold compared to 24 h (Fig. 24).

[0623] The accumulation of exopolysaccharide by the GIMC1402:EC-33P15 biofilm was also assessed dynamically. After 24 h, insignificant accumulation of exopolysaccharide was observed (Fig. 24). After 48 h, in a more mature biofilm, the amount of exopolysaccharide increases (Fig. 24), continuing to accumulate by 72 h of incubation (Fig. 24). The accumulation of exopolysaccharide after 72 h was 3.26 times higher compared to 24 h of incubation. The effect of FC5 on biofilm formation was also assessed dynamically after 24 h, 48 h, and 72 h. Incubation with FC5 for 24 h allowed inhibition of biofilm development by 3.3 times compared to the control (Fig. 24). After 48 h and 72 h of incubation with FC5, biofilm formation decreased 10-fold compared to the control (Fig. 24).

[0624] Incubation with FC5 reduced the accumulation of exopolysaccharide (Fig. 24) by 2 times after 48 hours, and by 4.8 times after 72 hours compared to the control.

[0625] The E. coli isolate GIMC1404:EC-33P55 of a different genotype formed a biofilm more actively after 24 h compared to the isolate GIMC1402:EC-33P15 (Fig. 25). The biofilm was formed over the entire surface of the well. After 48 h, the biofilm biomass increased, and after 72 h it had a denser structure due to increased interbacterial connections, compared to the 24-hour one (Fig. 25). The 72-hour biofilm has a denser structure due to increased interbacterial connections (Fig. 25), its biomass increased by 1.4 times compared to the 24-hour one (Fig. 25). The GIMC1404:EC-ЗЗР55 isolate actively produced exopolysaccharide after just 24 h, which was especially pronounced for the 48- and 72-h biofilms (Fig. 25). The increase in exopolysaccharide accumulation after 48 and 72 h was 2.5 times compared to 24 h. Incubation with FC5 reduced biofilm biomass by 2.5 times after 24 h, 5 times after 48 h, and 2.8 times after 72 h (Fig. 25). FC5 also affected exopolysaccharide accumulation, reducing its amount by 3.8, 3.7, and 4.5 times after 24, 48 and 72 hours, respectively (Fig. 25).

[0626] Example 20. Effect of FC5 on a model urogenital infection caused by C. trachomatis

[0627] C. trachomatis serotype DD / UW-3 / CX (ATCC VR 885) was grown in cycloheximide-treated McCoy cells using standard methods. The culture medium was minimal essential medium supplemented with 10% fetal bovine serum, 1% nonessential amino acids, 2 mM L-glutamine, 1% vitamins, and 0.5% glucose. Cell lysates containing approximately 3.5 x 10 4 inclusion units (IFU) per milliliter and stored at ~70°C. Female DBA / 2 mice weighing 20 g were injected subcutaneously with 33 mg / kg of the progesterone analogue proligestone (Covinan, Intervet Schering-Plough Animal Health, The Netherlands). Five days later, the mice were challenged with 10 6CFU / mouse C. trachomatis serotype D in 40 µl PBS. Control animals received sterile PBS. As a positive control, animals received azithromycin as a single daily oral dose of 10 mg / kg. Treatment was administered orally for 5 days to mimic the regimen often recommended for human treatment. FC5 was administered intraperitoneally at a dose of 50 or 100 mg / kg. Based on animal weight (20 g), the dose was 1 mg / mouse or 2 mg / mouse.

[0628] The effectiveness of the therapy was assessed by measuring the number of chlamydia in the vagina on day 14. The experimental results are shown in Fig. 26.

[0629] Example 21 Evaluation of the safety of the developed pharmaceutical composition in comparison with the prototype.

[0630] In order to assess the safety of the developed pharmaceutical composition and the prototype, the results of clinical study No. 02-FT-2017 (in which the prototype was studied) and the results of clinical study No. 05-FT-2021 (in which the developed pharmaceutical composition FK5 was studied) were compared.

[0631] Results of the safety assessment of the prototype in clinical study No. 02-FT-2017.

[0632] In the Phase I clinical study No. 02-FT-2017, a safety study of the drug Fluorothiazinone (prototype) was conducted with single and course use in healthy volunteers, with sequential inclusion of volunteers and dose escalation (study dates: August-December 2017).

[0633] The study population consisted of 25 healthy volunteers of both sexes aged 18-45 years inclusive. Volunteers in group 1 (n=5) received Fluorothiazinone (prototype) at a dose of 300 mg once, in group 2 (n=5) - at a dose of 600 mg once, in group 3 (n=15) - at a dose of 900 mg on the first day (loading dose of 600 mg, then after 12 hours a dose of 300 mg), and then at a dose of 600 mg for 5 days (300 mg 2 times a day). A total of 54 adverse events (AE) were recorded in the study, including 6 AE in group 1, 5 AE in group 2 and 43 AE in group 3.

[0634] Adverse events rated as “Very common - 1 / 10 prescriptions (>10%)” were:

[0635] • headache (44%);

[0636] • increased levels of creatine phosphokinase (CPK) (24%);

[0637] • increased alanine aminotransferase levels (20%);

[0638] • moderate decrease in fibrinogen (8%).

[0639] The following were classified as “Common – 1 / 100 prescriptions (>1% but <10%)”:

[0640] • dizziness (4%);

[0641] • drowsiness (4%);

[0642] • heaviness in the head (4%);

[0643] • stool retention (8%);

[0644] • flickering spots before the eyes (4%);

[0645] • symptomatic arterial hypertension (4%);

[0646] • increase in creatinine levels (4%);

[0647] • increased bilirubin levels (8%);

[0648] • increased levels of aspartate aminotransferase (8%);

[0649] • leukocytosis (8%).

[0650] All of these AEs were mild in severity, with the exception of one case of arterial hypertension, which was classified as a severe AE. The causal relationship was assessed by the investigator and rated as "Possible" and "Probable" for symptoms such as headache, dizziness, drowsiness, heaviness in the head, symptomatic hypertension, and increased ALT and AST; "Possible" for flashing spots before the eyes; and "Possibly not" or "Probably not" for fluctuations in fibrinogen, creatinine, CPK, bilirubin, and leukocytosis. Stool retention was rated as "Possibly drug-related" in one case and "Probably not related" in one case. All AEs did not require any action regarding the study drug and resolved spontaneously.Considering that all of the listed phenomena were assessed as adverse events of "mild" severity, and did not require the use of medication or other therapy, the overall safety profile of the drug, both with a single use and with the expected course of treatment, can be assessed as good.

[0651] Results of the safety assessment of FC5 in clinical study No. 05-FT-2021.

[0652] In the Phase I clinical trial No. 05-FT-2021, "An open-label study of the safety and pharmacokinetics of the medicinal product Fluorothiazinone, 300 mg tablet (Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation) with daily and course use with dose escalation in healthy volunteers," the safety of FC5 was assessed (study dates: June-July 2021).

[0653] A total of 35 healthy volunteers of both sexes, aged 18-45 years, were included in the study. The safety analysis included data from 30 volunteers, who were divided into dose groups to obtain PK5: 5 volunteers each in three high-dose daily groups (Group 1 - 1200 mg / day, Group 2 - 1800 mg / day, Group 3 - 2400 mg / day) and 15 volunteers in the fourth group of a course of treatment at a daily dose of 1800 mg for 7 days.

[0654] Adverse events (AEs) were coded according to the Dictionary of Medical Terms for Regulatory Purposes (MedDRA) version 24.0. The severity of AEs was assessed using the Classification of Common Terminology Criteria for Adverse Events (CTCAE V.5.0).

[0655] During the study, any AEs were reported in 1 / 5 volunteers in Group 2 (one AE), 1 / 5 volunteers in Group 3 (one AE), and 6 / 15 volunteers in Group 4 (9 AEs). A total of 11 AEs were reported in the study, including:

[0656] • gastrointestinal disorders:

[0657] o vomiting (1 AE) in group 3,

[0658] o gastritis (1 AE), diarrhea (1 AE), dyspepsia (1 AE) in group 4;

[0659] • disorders of the nervous system: headache (1 AE) in group 2,

[0660] about 3 AE in the form of headache and 1 AE “dizziness” in group 4.

[0661] • urethritis (1 AE),

[0662] • increase in the number of leukocytes (1 AE) in group 4.

[0663] All reported AEs were mild. Only three AEs in group 4 (diarrhea and two cases of headache) and vomiting in group 3 were considered possibly related to the drug. The remaining AEs were of questionable drug-related nature. All clinical AEs resulted in recovery; the outcome was only rated "unknown" for the AE of increased white blood cell count.

[0664] No SAEs, including fatal outcomes, other SAEs, or other significant AEs, as well as clinically significant abnormalities in the results of physical examination, vital signs, blood and urine laboratory parameters, and ECG, were recorded.

[0665] Overall, FK5 is well tolerated with high-dose daily administration with dose escalation (in three dosages: 1200 mg, 1800 mg, and 2400 mg), as well as with course administration in healthy volunteers. During this study, mild, non-serious adverse events were reported, primarily gastrointestinal and nervous system disorders. No SAEs, including fatalities, other SAEs, or other significant AEs were recorded. No abnormalities related to IN administration were observed in laboratory parameters, physical examination results, vital signs, or ECG.

[0666] The results of both clinical studies (both the prototype and the developed formulation) demonstrated that the drugs were well tolerated. All reported adverse events were rated as mild and did not require medication or other therapy. Thus, it can be concluded that 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide has a favorable safety profile, which remained unchanged with increased bioavailability of the active ingredient in the developed pharmaceutical substance.

[0667] The given examples confirm the possibility of creating a pharmaceutical substance for the formation of antibacterial drugs based on 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide, a pharmaceutical composition based on it and their industrial applicability.

Claims

Invention formula 1. A pharmaceutical substance for the formation of antibacterial medicinal products containing 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide, wherein the active substance is contained in the form of particles that have a modal size less than or equal to 45.9 μm.

2. The pharmaceutical substance according to claim 1, characterized in that 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide has a crystalline form.

3. The pharmaceutical substance according to claim 1, characterized in that 4-(3-ethoxy-4-hydroxybenzyl)-5-oxo-5,6-dihydro-4H-[1,3,4]-thiadiazine-2-(2,4-difluorophenyl)-carboxamide has an amorphous form.

4. The pharmaceutical substance according to claim 1, characterized in that the modal particle size is 45.9 μm.

5. The pharmaceutical substance according to claim 1, characterized in that the modal particle size is 40.8 μm.

6. The pharmaceutical substance according to claim 1, characterized in that the modal particle size is 10.0 μm.

7. The pharmaceutical substance according to claim 1, characterized in that the modal particle size is 7.1 μm.

8. A pharmaceutical composition with antibacterial action, containing a pharmaceutical substance according to paragraphs 1-7 and pharmaceutically acceptable excipients.

9. The pharmaceutical composition according to claim 8, wherein the pharmaceutically acceptable substances are selected from a filler, a disintegrating agent, a surface modifier, a binder, a glidant.

10. Use of the pharmaceutical composition according to paragraph 8 for obtaining the finished dosage form of a tablet.

11. Use of the pharmaceutical composition according to paragraph 8 for obtaining the finished dosage form of a powder.

12. Use of the pharmaceutical composition according to paragraph 8 for antibacterial therapy in mammals.

13. Use of a pharmaceutical composition according to claim 12, wherein antibacterial therapy is carried out against pathogenic bacteria.

14. Use of a pharmaceutical composition according to claim 12, wherein antibacterial therapy is carried out against opportunistic bacteria.

15. Use of a pharmaceutical composition according to claim 12, wherein antibacterial therapy is carried out against bacteria with an extracellular type of parasitism.

16. Use of a pharmaceutical composition according to claim 12, wherein antibacterial therapy is carried out against bacteria with an intracellular type of parasitism.

17. Use of a pharmaceutical composition according to claim 12, wherein antibacterial therapy is carried out against bacteria that cause acute infections.

18. Use of a pharmaceutical composition according to claim 12, wherein antibacterial therapy is carried out against bacteria that cause chronic infections.

19. The use of a pharmaceutical composition according to claim 12, wherein antibacterial therapy is carried out against bacteria that cause recurrent diseases.

20. The use according to claim 12, wherein the pharmaceutical composition is administered simultaneously with an antibiotic.

21. The use according to claim 12, wherein the pharmaceutical composition is used as monotherapy.

22. Use of the pharmaceutical composition according to paragraph 12 for the prevention of nosocomial infection.

23. The use according to claim 22, wherein the nosocomial infection is nosocomial pneumonia.

24. The use according to paragraph 12, which is realized by inhibiting the growth of biofilms.

25. The use according to paragraph 12, which is realized by reducing the motility of bacteria.

26. The use according to paragraph 12, which is realized by reducing the virulence of bacteria.

27. Use according to claim 12, wherein the pharmaceutical composition is used in mammals at a dose in which the content of the active substance is from 1 mg to 12600 mg.

28. Use according to claim 27, wherein the pharmaceutical composition is used in mammals at a dose in which the content of the active substance is 300 mg, or 600 mg, or 1200 mg.